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ABSTRACT
FAST ISOTOPE RATIO MASS SPECTROMETRY (FIRMS): A TANDEM MASS
SPECTROMETRY TECHNIQUE FOR THE RAPID AND SEMI-COMPREHENSIVE
EVALUATION OF ISOTOPE RATIOS

FREDRICK OCHIENG

2018

Isotope ratios (IRs) are a measure of the variation in abundance of light isotopes versus
heavy isotopes of an element, e.g. 1H/2H,12C/13C, and

14

N/15N. Because IRs change as a

molecule undergoes certain chemical and physical processes, they represent unique
fingerprints that can be used to trace the source of a chemical compound. Current
techniques for determination of IRs each have major limitations, such as loss of structural
information, vulnerability to contamination, high cost, large sample size requirements, low
precision, limited applicability, and lengthy analysis. Fast Isotope Ratio Mass
Spectrometry (FIRMS) was developed as a next-generation analytical technique for robust
measurement of IRs using tandem mass spectrometric data. Based on the FIRMS nonlinear
mathematical model, the difference between predicted and experimental tandem mass
spectrometric data was minimized by modifying isotopic fractional abundances of the
atoms involved. FIRMS was used to calculate the isotope abundances of molecules of 17
compounds. FIRMS produced excellent precision, with IRs standard deviations of less than

xviii
1‰, for 13C compared with IRMS in a fraction of the time. FIRMS also produced
excellent accuracy for 13C values with an absolute error of less than 1.6‰ compared to
IRMS. It was also successfully coupled with LCMSMS to analyze 13C for DIMPA,
caffeine and acetylsalicylic acid with standard deviation of less than 1‰ and accuracies
within 1‰ compared to IRMS. The bivariate plot of FIRMS versus IRMS showed an
excellent R2 of 0.992 with a slope of 1, validating the new technique as an accurate isotope
ratio measurement technique. FIRMS offers several advantages over other methods of IR
determination, and may ultimately become the preferred method for determination of IRs.
The disciplines that will benefit from development of FIRMS include: 1) forensic science,
2) environmental chemistry, 3) geology, 4) geochemistry, 5) cosmochemistry, 6) food
sciences, 7) earth science, and 8) pharmaceutical science. FIRMS will make IR analysis
more widely available, fast and less expensive for scientists to conduct research in these
fields, as well as train new graduate students for future scientific research and development
in this area.

1
CHAPTER 1: Introduction
1.1 Motivation and Objective
Counterfeiting is a threat to every aspect of the world economy, including
innovation, technology, and industrial relations, such as production and manufacturing.
Commonly used materials and products that require incredible input in research,
development and marketing are frequently targeted.1 Counterfeiting has grown into
enterprise primarily because of weak regulation in many countries. Research shows that
the regulations target the supply of fake goods and do not address the high consumer
demand for cheap and affordable products. 2 3
Thus, tools and mechanisms must be put in place to fight the supply of
counterfeited products. For example, developing a fast and reliable technology capable of
tracing the source of counterfeit products made from organic materials can be used to
determine the authenticity of goods. Tracing organic products is possible because
chemical compounds are composed of atoms, most of which have stable isotopic forms.46

Using isotope tracing methods 7-9 and carbon dating10 products can be authenticated.
Isotope ratios (IRs) are used to trace the history of compounds and a measure of

the ratio abundance of light isotopes versus heavy isotopes of an element, such as 1H/2H,
12

C/13C, 14N/15N, 35Cl/37Cl and 79Br/81Br. These ratios are largely quite consistent, with

the original isotope frequencies of each terrestrial element fixed upon the formation of
the earth.11 But, experimental observations show changes in relative isotope abundances
occur over time due to natural phenomena, 11 including radioactivity,12-13 anthropogenic
activities,14 cosmic ray interaction,15-17 and fractionation.11 Radioactive decay affects IRs
by reducing the abundance of heavier isotopes, such as 13C, 34S and 81Br12. Cosmic rays,

1

2
which occasionally enter the earth’s magnetic field, may result in neutron capture,
thereby changing the isotope ratios of certain atoms. 17-19 For example, 36Cl formation
occurs when 35Cl captures neutrons produced in muon capture and muon-induced
photodisintegration reactions. 20 Anthropogenic activities, such as industrial nuclear
reactions and mining affects IRs by enriching some isotopes.21 Fractionation is a process
where different isotopes of an element produce slightly different chemical and physical
properties, resulting in changes in isotope ratios as molecules undergo certain chemical
and physical processes.22 For example, in biological processes, some factors, such as
genetics, affect the fractionation process as plants utilize CO2 for photosynthesis. Plant
types follow different photosynthesis pathways and processes that result in unique IRs.
These ratios from each plant food source become integrated into an animal’s biology
based on their diets. Table 1.1 shows the photosynthetic cycle and 13C values for
different plant types (i.e.,  is a measure of 13C/12C compared to a reference material and
represented as a “per mil” or parts per thousand, denoted as ‰).
Table 1.1. Photosynthesis cycle and 13C values of different plants
Plant type

C3 (dicotyledonous)
C4 (monocotyledonous)
C3/C4

Photosynthesis
cycle

Examples

13C values range (‰)

Calvin-Benson

Wheat and beans

-23 to -2223

Hatch-Slack

Millet and corn

-8 to -20 23-24

Benson and HatchSlack

Pineapples and
orchid flower

-10 to -3411

The change in IRs as a molecule undergoes certain chemical and physical
processes represents unique fingerprints that can be used to determine the history of a
2

3
chemical compound. For example, animals from North America are distinguished from
European animals because of different 13C values. European meat products have lower
levels of 13C because they feed on C3 plants, while North Americans have higher 13C
values because they feed on C4 plants.11
Although IRs are extremely important in a number of areas, it continues to be
very difficult and costly to determine IRs from currently available techniques. Thus, the
objective of this study was to develop a laboratory-based analytical technique, known as
Fast Isotope Ratio Mass Spectrometry (FIRMS), as a next-generation analysis method.
FIRMS uses tandem mass spectrometry data and a nonlinear mathematical model
describing the probability of compound fragmentation to extract IRs of locations of
individual atoms or groups of atoms within a molecule. It is a rapid, accurate, sensitive,
robust, and more comprehensive method that evaluates IRs with promise to definitively
identify the source/history of the chemical components of the material.
1.2 Importance of isotope ratios (IRs)
Isotope ratios (IRs) have remained a significant area of research interest for many
decades as documented by the number of scientific publications. Applications of IRs
have grown over time in areas that include forensic science, food and drugs analysis, diet,
biochemistry and metabolism, doping investigations, and environmental pollution.11
Figure 1.1 shows the number of publications based on isotope research work from the
year 1950 to 2017. The figure shows that the number of publications with IRs as a subject
of interest greatly increased over the past seven decades, especially from 1950-1990.11

3

4

No. of publications (x103)

45
40
35
30
25

20
15
10
5
0
1950

1960

1970
1980
1990
2000
Year published (measured in decades)

2010

2020

Figure 1.1. Shows the number of publications per decades for IRs research from the year
1950 to 2017 obtained from Google Scholar on May 4, 2017.

In forensic science, IRs have been used to identify the source of counterfeit
materials by linking the evidence to a particular geographical place or a person.25 In the
past, these materials have included: explosives, ignitable liquids,25 illicit drugs,25-26
prehistoric evidence,27 and nuclear arms.28 For food, beverage, and water safety IRs are
used to identify the origin of products,29-31 confirm if components indicated by food and
beverage manufacturer agree with the actual content of the product, and to analyze
pollutants in drinking water.11 IRs are also used to establish the dietary pattern, metabolic
class, and movement of domestic animals such as cattle.11 In suspected athlete doping
activities, IRs are used to analyze performance enhancing compounds that are thought to
be synthetic. For example, gas-chromatography IRMS (GC-IRMS) has been used to
analyze carbon isotope ratios of nandrolone (NAD). NAD is an endogenous steroid
hormone metabolite used by some athletes, or in racehorses to enhance performance.32
Similarly, elemental-analyzer IRMS (EA-IRMS) has been used to distinguish between

4

5
endogenous and exogenous concentrations of synthetic steroid 19-norandrosterone, a
metabolite of 19-nortestosterone by using isotopically labeled standards to compare
isotopic carbon ratios and determine the origin of urinary norandrosterone.33
Environmental pollution agencies (e.g., U.S. EPA) employ GC-IRMS methods for
pollution control and health safety to analyze carbon isotopes of pollutants, such as
polycyclic aromatic hydrocarbons (PAHs), to identify the source of pollutants.11, 34
In recent years, IRs have been expanded to include identification of counterfeit
drugs. Counterfeiting medicine has led to a significant number of fatalities. According to
World Health Organization (WHO), substandard, spurious, falsely labeled, falsified and
counterfeit (SSFFC) products have continued to undermine the treatment of deadly
diseases such as malaria and tuberculosis. WHO has reported that counterfeit drugs
include over 920 medical products, such as therapeutics, and generic medicines,
antimalarials and antibiotics as the most counterfeited drugs globally.35
Counterfeit drugs disproportionately exist in illegal markets (unregulated
pharmacies, clinics, and hospitals) and online. Their production is done under unhygienic
conditions by unqualified workers. These false medicines might contain nonmalignant
ingredients such as flour, sugar, and pollen, instead of active pharmaceutical ingredients
(API); may contain lower doses of the API than the authentic drug; may contain
components, such as aspirin that are capable of feigning treatment; or an entirely illegal
API that can be poisonous.35
Falsifying products is a practice that has thrived because of the limitations of
current technologies as well as weak laws. Given the complexity and effects of the
problem, it will require a number of complementary technologies to combat, including a

5
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technology that allows rapid and robust determination of IRs in raw materials and
products made from natural compounds. Organic compounds are ubiquitous in essentially
all products that could be counterfeited. Additionally, this technology could be extended
to analyze organic pollutants and biological samples collected from crime scenes for
forensic analysis and other applications. If the technology developed can determine the
source of a chemical compound, it will give organizations such as law enforcement the
ability to investigate and arrest criminal entities involved in manufacturing and selling of
illegal medicine, food and other consumer products.
1.3 Effects of counterfeit medicines
1.3.1 Public health
Countries with a weak regulatory system for imported and locally produced
medicine often experience public health crises because of SSFFC products. In such
countries, a safe and reliable quality medicine supply for health care is almost nonexistent.36 Thus, these countries experience a high level of untreated disease, deaths and
treatment failures based on counterfeit medicines.37
A significant number of fatalities have been recorded over the years as a result of
SSFFC medicine. For example, in 2008 and 2009, 84 Nigerian children died from acute
kidney failure due to presence of diethylene glycol (an active ingredient in antifreeze) in
a counterfeited teething syrup.38-39 The same diethylene glycol was sold to a European
company as pharmaceutical-grade glycerin by a Chinese chemical manufacturer. It killed
219 people from acute kidney failure in Panama in 2007.40 In the Panama case, the
confirmed deaths could be a mere fraction of total mortality given that 60,000 bottles of

6
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cough syrup were contaminated, as reported by the Panama Ministry of Health and
WHO.41
Another example of the effect of falsified medicine is the rise of untreated
diseases that progress over time, eventually leading to deaths. There is evidence of such
cases documented from parts of the world where it is too costly to have the technology to
verify and authenticate or evaluate the quality of medicine. For example, in Ghana
researchers found that 89% of the uterotonic drugs oxytocin and ergometrine did not
meet the required standards by British Pharmacopoeia specification, and 2% of the
medicines were expired. In this case, only 9% of the drugs were found effective in curing
the intended diseases.42 Hemorrhage, a treatable condition using uterotonic medicine, is
the main cause of a high maternal mortality ratio in Ghana estimated to be 350 per
100000 live births.43-44 That means hemorrhage accounts for an estimated 17 to 22% of
maternal deaths in Ghana. 45
Treatment of chronic diseases such as diabetes has increasingly become a serious
challenge to health institutions because cheap counterfeit drugs have flooded the health
industry affecting health quality. For example, in China, a fake version of the diabetes
drug, glyburide, was found to have six times the pharmacopeial standard dose and
resulted in the death of two patients.46 Fifty percent of popular brands of the oral diabetes
drug metformin failed several pharmacopeial tests of bioequivalence, thus directly or
indirectly affecting 80% of 347 million diabetic patients who live in developing
countries.47-48
Antibiotics, which are the most important medication for infectious diseases
globally, are also targeted by counterfeiters. Substandard antibiotics account for about
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45% of the 771 counterfeit cases documented and reported by WHO.49 Therefore, a large
number of antibiotics, such as penicillin and amoxicillin commonly used for treating
bacterial infections, including scarlet fever, respiratory and urinary tract infections, and
pneumonia, are counterfeit.37 It is worth noting that bacterial Pneumonia, which is caused
by the pathogen Streptococcus pneumoniae, accounts for 12% child deaths globally.50
Lastly, counterfeit drugs can also lead to catastrophic treatment failures, such as
bacteria, and virus drug resistance, based on incorrect API concentration. Bacteria
resistance is problematic to health research plans, health systems, health care providers
and people seeking medical care. Such resistance can jeopardize decades of research and
development of medicine. There are already such cases reported by healthcare providers
and health institutions. For example, many tuberculosis drugs have been reported to be
ineffective for treatment because Mycobacterium tuberculosis, the bacterium causing
tuberculosis, has gradually become drug resistant.51 This bacterium accounts for nearly
6% of global drug-resistant infections.52 Often, these infections are complex and
challenging to treat, and are responsible for multiple deaths around the globe. 53-59
1.3.2 Economic and social impact of counterfeit drugs
The cost of manufacturing drugs, from research to production, is currently
estimated to be more than $1.3 billion.60 Figure 1.2 shows the estimated increase in drug
development cost since 1975. Since most drug research is tax funded by citizens, the cost
is often transferred to consumers. For many families in middle-income and poor
economic status, increasing drug prices create financial difficulties. In many cases,
prescription costs are second after food and house expenses in many countries.61 When
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bacteria and viruses develop drug resistance, it renders drugs ineffective that cost billions
of dollars to produce. This drives the cost of developing drugs higher.62-64
The high cost of developing medicine creates a situation where these treatments
become too expensive to afford, and also drives health insurance costs higher.62 This can
lead to corruption in health institutions, in which only those who can afford it have access
to the best medicines.61 Organized crime and terrorist activities can also be funded by
counterfeit medicines.65. All these cases are not good for the economy and have a
negative impact on the social welfare of communities.
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Figure 1.2. The increase in the cost of drug development since 1975.

Overall, counterfeit pharmaceuticals can lead to mass poisoning, disease
progression, drug resistance, and increase in deaths resulting from chronic diseases, high
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drug costs, loss of confidence in health systems, health care providers, medicine and
national and international regulatory agencies, and funding of criminal and corrupt
enterprises.
1.4 Overview of Techniques for Detecting SSFFC
The impact of SSFFC on health care, social life and economy of many countries
around the world is severe. Thus, there is a critical need to develop technologies to
examine and analyze counterfeit products. Visual inspection can sometimes identify
counterfeit goods, such as currencies, relevant documents, antiques, and medicines.65
The conventional optical technologies available for detecting SSFFC from the WHO
Checklist,66 are multidimensional atomic force microscopy,67 GPHF-MiniLab68-69 and
Counter Detection Device (CD-3).70-71 The WHO checklist is freely available for
healthcare workers including pharmacy and laboratory technicians with minimum
training requirements.66 Atomic microscopy authenticates products by reading the
molecular watermarks imprinted on products. It is expensive, requires a climatecontrolled environment and a well-trained scientist to operate and maintain it. 67 Visual
inspection in many cases is a first step in authenticating materials, and other additional
advanced technologies are required to identify SSFFC because many counterfeiters have
already developed technology that can evade hi-tech visual inspections.64 The advanced
technologies needed in addition to visual inspection include portable technologies and
analytical laboratory techniques.
Large instruments cannot be utilized in certain areas, such as remote locations,
ports, and pharmacies. Thus, mobile devices for detecting counterfeit products are
employed. They include Counterfeit Detection Device (CD-3),70-71 Nuclear Quadrupole
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Resonance (NQR),72-73 Raman,74-75 near-infrared (NIR) light spectroscopy,76-77
chromatography techniques,78 Fast Chemical Identification System (FCIS),79 and GPHFMiniLab.68-69
These techniques have several advantages because they are cheap technologies
(e.g., chromatography techniques that include TLC Speedy Apparatus, and CD-3) except
Raman and NIR portable devices. In all cases, they do not require sample preparation,
they are portable, and relatively fast in analyzing samples. Additionally, they do not need
extra supplies and call for minimal training time. However, CD-3, Raman, and NIR
portable devices have a limitation because they depend on the use of reference libraries of
pharmaceuticals to identify counterfeit products.80 Dependence on reference libraries
causes problems especially if malicious individuals have access to the database. 80They
are also incapable of analyzing complex matrices that are uniquely identical such as
enantiomer mixtures, or the same compounds produced from two different sources. Thus,
complex forms and analysis of the same compounds from various sources require
advanced laboratory-based analytical techniques for IR analysis discussed in Chapter 2.
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CHAPTER 2: Currently available IR analysis methods
2.1 Analytical laboratory technology for IRs analysis
There are several techniques available for evaluating IRs. Isotope Ratio Mass
Spectrometry (IRMS),11 Nuclear Magnetic Resonance (NMR) Spectroscopy,81Infrared
Laser Absorption Spectroscopy (ILAS) and Cavity-Ring Down Spectroscopy (CRDS). 8283

CRDS, IRMS and NMR are the most commonly used for counterfeit detection.

2.1.1 Infrared Laser Absorption Spectroscopy (ILAS)
ILAS was developed as an alternative to the established IRMS for the
measurement of IRs of atmospheric CO2. It uses the mid-IR spectral region that allows
measurements of IRs with high-sensitivity due to rotational-vibrational bands of strong
and important vibrations that affect CO2 in the region. It also uses fast scan rate to
acquire spectra that increases sensitivity; for example, 1400 spectra / s at 1.4kHz for IRs
calculations.84-90
It has an advantage over IRMS because mass isotopologues are eliminated based
on distinctive absorptions by of trace gas molecules. ILAS is also cheap, consumes less
power and benchtop space, and does not require high purifications and highly purified
gases. However, it is not efficient for batch analysis in a laboratory set up except for
medical detection and diagnosis of infections such as H. pylori through human breath.
But it requires large amounts of CaCO3 for that type of analysis which is unfeasible in
most earth science research.87, 90-91
ILAS was recently improved using a more sensitive tunable infrared laser direct
absorption spectroscopy (TILDAS) shown in Figure 2.1. It uses a quantum cascade laser
(QCL) at 2310 cm-1 to measure absorption spectrum of CO2 isotopologues (i.e., 12C16O2,
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C O16O, 12C17O16O and 13C16O2) shown in Figure 2.2. The miniaturized absorption cell

is vacuum tight, and allows CO2 to flow into a pre-evacuated cell and then be separated at
a low pressure and detected by a thermoelectrically cooled photovoltaic detector. For
each isotopologue the output is calculated using nonlinear least-squares fitting of the
absorption spectrum and produces a peak area that is used to find a ratio with other peaks.
The calibration is done against CO2 derived from standard carbonates with known stable
IRs.92

Figure 2.1. A schematic diagram of isotope ratio measurement system. It consists of a
CaCO3 reaction unit, CO2 purification unit, and tunable infrared laser absorption
spectroscopy (TILDAS) system. TILDA, shown highlighted in orange has multipass cell
and two valves.92
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Figure 2.2. CO2 absorption spectrum acquired by TILDAS technique with a 36 m
absorption path at 10 Torr (1333 Pa) total pressure. The measured spectrum is marked
green with a fitting marked as black. The black dotted line represents the fit background.
The horizontal axis shows the quantum cascade laser (QCL) that scans the laser
frequency range by means of 800 channels at 1.4kHz.92
2.1.2 Nuclear Magnetic Resonance (NMR) Spectroscopy
NMR methods have several advantages that are fundamental to their applications.
They are non-destructive.93 They can be faster than chromatographic techniques.94 SSNMR spectroscopy is capable of analyzing both active pharmaceutical ingredients (API)
95-96

and the excipients,97-99 and is well-suited for the study of polymorphism100 because it

can differentiate conformational polymorphism from stereochemical differences.96 When
compared to powder X-ray diffraction (P-XRD), NMR is capable of analyzing chemical
compounds in the amorphous state101-102 of different patterns of generic drugs in the
spectrum81 103 thus widely applied in the analysis of counterfeit e.g., analysis of acetyl
vardenafil (i.e., API in viagra) and vardenafil shown in Figure 2.3. But NMR does not
analyze IRs and requires a large concentration of API, because it produces signals with
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low intensity that might be suppressed or overlapped by signals from excipients96, 104 93
Thus, it is hard to use NMR in cases where impure or limited material is available.
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Figure 2.3. The structure of acetyl vardenafil (A) and vardenafil (B).

Unlike general NMR used for structural analysis of compounds, Site-specific
Natural Isotope Fractionation NMR (SNIF-NMR) is used to determine hydrogen (2H
SNIF-NMR) and carbon (13C SNIF-NMR) isotope ratios of organic compounds with
excellent accuracy. SNIF-NMR has the major advantage of measuring the isotope ratios
at individual locations in a molecule without converting compounds to gaseous products
through combustion.81 For example, SNIF 13C NMR employs the method of 180
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quantitative adiabatic composite refocusing 13C NMR pulse sequence for site-specific
isotopic measurements by determining 13C/12C site-specific isotope ratios.105-107
SNIF-NMR is built on the principle of natural isotopic fractionation and is
regularly used to authenticate food. For SNIF-NMR function the molecules used must be
purified or pure. The method involves, for example, the fermentation of juice,
quantitative extraction of alcohol (e.g., ethanol) by the process of distillation, preparation
of samples for NRM analysis, NRM acquisition and interpretation of results.108-109
For the interpretation of the site-specific isotope ratio, 𝑅𝑖 , of a given molecular
site, 𝑖, is defined as (𝐷⁄𝐻)𝑖 = 𝐷𝑖 ⁄𝐻𝑖 where 𝐷𝑖 is the number of deuterium atoms at site 𝑖
and represents the number of isotopomers mono-deuterated at site 𝑖. 𝐻𝑖 , is the total
number of hydrogen atoms of type 𝑖, which is equivalent to 𝑃𝑖 𝑁𝐻 where 𝑃𝑖 is the number
of equal positions at site 𝑖 and 𝑁𝐻 the number of fully protonated molecules.110
Another important parameter that is used to quantify experimental data is 𝑅𝑖/𝑗 also
defined as 𝑅𝑖/𝑗 = 𝐹𝑗 𝑆𝑖 ⁄𝑆𝑗 where S is the intensity of signal 𝑖 or 𝑗 (i.e., the area of the
NMR signal). 𝑅𝑖/𝑗 represents the number of heavy isotopes at site 𝑖 in circumstances
where site 𝑗is randomly given its known stoichiometric number of atoms, 𝐹𝑗 . Using this
information, SNIF can access directly and simultaneously the hydrogen isotope ratios,
(D/H) relative to different positions, 𝑖, in a given molecule.110
Overall, NMR methods developed to analyze 13C/12C and 2H/1H isotope ratios for
specific atomic sites in organic compounds and to study isotope ratio patterns of complex
organic molecules have numerous applications.106, 111-114 They are used to analyze and
authenticate food such as wine, sugar, fruit juices and olive oil.115 It has also been
employed in determining the geographic origin of heroin and cocaine in illegal drug trade
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investigations.116 However, technical limitations of NMR include relatively low precision
(~1 per mil), large samples size requirement (mg or greater), long integration times, and
low sensitivity.114
2.1.3 Cavity Ring-Down Spectroscopy (CRDS)
CRDS is an efficient technique for determining 13C/12C117 ,16O/17O and 2H/1H118
IRs based on the relative absorption lines of carbon dioxide, water vapor118-119 and
methane.118 It operates by tuning a laser source to the spectrophotometric absorption lines
of interest and measuring the decay rate of the light intensity, 120 which allows
determination of the relative abundance of isotopes of interest.
CRDS has the advantages of accurate quantitative measurements, speed, and
simplicity. However, it has several limitations, since it suffers from low selectivity and
low sensitivity. Combustion of compounds is necessary for CRDS, leading to loss of
structural information which allows for determination of the aggregate isotopes for one
element at a time. It is prone to inconsistencies because of the delicate mirrored surfaces
necessary to perform the technique. CRDS is commonly used to determine IRs of only
carbon, hydrogen, and oxygen. 120 Despite the fact that nitrogen and sulfur isotopes have
been analyzed via optical techniques they are rarely analyzed using CRDS for most
organic compounds. 118-119
2.1.4 Isotope Ratios Mass Spectrometry (IRMS)
2.1.4.1 Background
Forensic, geological and environmental scientists widely apply IRMS for tracing
origin/history of materials. Many IRMS applications have emerged in the past four
decades, notably study of the stable isotopes at the natural abundance. The concept of
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IRMS can be traced back to 1918 by A. J. Dempster.121-122 Alfred Nier built the original
version of the IRMS in 1936 that featured a 180° magnetic sector field analyzer. It was
used to determine significant isotopic data122-123 in wood, oil and other biogenic materials
for 13C depletion. Later in 1947, Nier introduced a modern day IRMS that featured
multiple collectors and a magnetic sector mass filter.122-124 IRMS technique became a
standard instrument for the geosciences and other related fields almost immediately after
World War II. By 1950, IRMS had been used in studies of systematic variation of
13

C/12C, and fundamental depletion of 13C in organic materials.122, 124 Modern IRMSs

(schematic diagram shown in Figure 2.4) retain most of the original features, but a novel
interface, called continuous flow interface, was developed derived from the principle of
viscous flow of carrier gas continuously spiking bands of sample gas into the ion source.
The continuous flow method enabled online coupling of different analytical techniques
with IRMS. With this coupling ability, sample signals are transient and appear as peaks.
A special algorithm has since been created to calculate isotope ratios from signal/peaks
accurately.122, 125 The continuous flow interface has also eliminated analytical errors due
to increased pressure in the ion source.122, 126
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Figure 2.4. Schematic diagram of modern-day IRMS.11

The first interfaced continuous-flow isotope ratio mass spectrometry (CF-IRMS)
unit was introduced by Preston and McMillan when they coupled an elemental analyzer
to an IRMS via a variable leak.127 Among other improvements was the ability of IRMS to
analyze 15N labeled compounds, introduced in 1978.128 Around 1984, IRMS was
integrated with gas chromatography (GC) via a combustion unit for GC-C-IRMS. This
eventually allowed analysis of stable isotope ratios at natural abundance.122, 129 Currently,
two types of IRMS are available, the Elemental Analyzer (EA-IRMS), used for analyzing
C and N, and the High-Temperature Thermal Conversion EA-IRMS (TC-EA-IRMS)
used for analyzing H and O isotopes.11

2.1.4.2 EA-IRMS and TC-EA-IRMS
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In EA-IRMS, shown in Figure 2.5, a sample is initially subjected to elemental
analysis by being combusted at 900C to produce N2, NO, NO2, H2O and CO2 in the
presence of an oxidant, such as copper or chromium oxide. A reduction process follows
in a stream of helium before determination of the relative abundance of isotopes in the
sample via IRMS. On the other hand, the analysis process in TC-EA-IRMS shown in
Figure 2.6 involves the thermal conversion of sample in a reactor at elevated
temperatures (usually > 1000C) in the presence of reactive C in a continuous flow of
He.130

Figure 2.5. Schematic diagram of an EA-IRMS for the analysis of 13C and 15N.131

In both IRMS techniques, a sample is quantitatively converted into a gas (with
approximately identical molecular weight) and chromatographically separated by a GC
before introduction into the ion source of the IRMS. The gaseous sample undergoes
ionization by producing a highly charged gaseous species, 132 for example, CO2+, N2+,
and H2O+ ions. 133-135 The ions produced travel in the form of ion beams accelerated to,
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e.g., 10 keV relative to the ground passing through an electrostatic analyzer (ESA) before
entering the magnetic field. The ion beam then goes through the rotation and focusing
quadrupole lenses before inflowing to the magnetic sector electromagnet controlled by
feedback from a field probe. After the ion beam exits the magnet, they pass through a
second focusing quadrupole before reaching the detector array.114 When the ions reach
the mass analyzer, they encounter a multi-collector array containing eight pairs of
detectors, each pair consisting of an electron multiplier and Faraday cup adjacent to one
another. The electric

Figure 2.6. Schematic diagram of TC/EA-IRMS for the analysis of 2H and 18O.131
currents produced by ion beam are registered in Faraday cups and recorded as signals.114
Then, IRs are measured by monitoring ion current intensity at selected m/z ratios. For
example,18O/16O is found by monitoring m/z 46 and 44, which are the molecular masses
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of [12C16O18O] + and [12C16O16O] + ion, respectively.130 The IR is reported as  (parts per
mil) calculated using Equation 1.11, 114
𝑅𝑠𝑎𝑚𝑝𝑙𝑒

𝜕 = (𝑅

𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑

− 1) 𝑥 1000

(1)

where  is the value of the ratio of sample and standard measured, Rsample is the ratio of
the isotope of samples, and Rstandard is the ratio of the isotope of the standard.11
2.1.4.3 Advantages and disadvantages of IRMS
In general, IRMS is considered the most accurate, precise and reliable method for
determining IRs. It is exceptional for analysis of total IRs of specific elements in
compounds. Additionally, it has several significant strengths: 1) its Nier-type electron
impact (EI) ion source can generate excellent currents (nA to A) and stable ion beams;
2) its multiplier-collector arrays allow very precise measurements of small relative
differences in isotopic compositions; 3) the dual viscous-bleed inlet system used on many
gas source IRMS allows fast comparison of sample and standard under identical
conditions, producing excellent accuracy.114, 136-139
Overall, IRMS is exceptional for determining aggregate IRs of compounds.
However, the current IRMSs also have limitations that affect the extent to which they
measure IRs. IRMS analytes must be gases mostly of low molecular weight with a
significantly high vapor pressure at standard room temperature for delivery to the EI ion
source with a carrier gas. IRMSs detect ions using only Faraday cups, which are good for
linearity but have significant background currents (~fA) which increases detection
limits.128, 140-141 IRMSs also have low mass resolving power (~200), significantly lower
than most complex thermal, plasma and secondary ion mass spectrometers (~10,000)
(measured as mass M/M; M is width which is equivalent to a mass unit of the ion
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beam). The low resolution means that IRMSs are incapable of differentiating analyte ions
from isobaric interferences, including contaminant gases. For example, H16O, and 13CH4
at 17 amu, or 12C16O22H+ and 13C16O2H+ at 45 amu, and the isotopologues of the same gas
that share cardinal mass e.g., 13CH4 and 12CH3D; a phenomenon defined as isotopic
isobars. Thus, IRMSs are mostly used to measure specific analytes that can be easily
purified, with less significant isobaric interferences and ubiquitous vacuum contaminants
with a simple stoichiometry that ion-correction schemes can deconvolve, at least for
some of their isotopic isobars.114 Compounds analyzed by IRMS must be highly purified,
otherwise impurities from solvents, and other contaminants might affect IRs obtained.
For example, during isolation of compounds from plants or drugs, achieving adequate
purification (i.e., close to 100%) is very difficult. IRMS is a very sophisticated technique
that is difficult to implement, especially for certain elements. For example, Br and Cl IR
measurements are quite involved, since they require conversion of Br and Cl compounds
to other products, such as HCl142 which requires additional sample preparation methods,
such as SPME.143 Also, IRMS methods lead to loss of all structural information11 such
that only aggregate isotope ratios are available at the end of analysis due to combustion
of compounds to produce gases, such as CO2, N2, H2O or NO2. Lastly, IRMS is limited to
analysis of one element at a time.
Collectively, the existing IRs analysis techniques and methods have played
important roles towards the advancement of isotope research and studies. However,
given their limitations, there is a critical need for a new method for IRs analysis which is
fast, sensitive, selective, inexpensive and relatively easy to implement. It should be able
to determine IRs for locations of individual atoms or groups of atoms simultaneously and
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have the ability to determine IRs for all elements simultaneously. The method should
have the ability to easily analyze isotopes that are difficult, such as Br and Cl.
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CHAPTER 3: Fast Isotope Ratios Mass Spectrometry (FIRMS)
3.1 Introduction to FIRMS
We developed FIRMS as an alternative method for IR analysis due to the
limitations of IRMS. It is a novel, unique and potentially transformative technology that
accurately and precisely predicts isotope ratios for elements in a compound in a fraction
of the time of other methods. It calculates separate isotope ratios for individual atom
locations or portions of the molecule. FIRMS has the potential to also calculate IRs that
are difficult to determine (e.g., S, Cl, and Br), and to determine the IRs of all elements in
a molecule simultaneously. It is the first IR analysis technique to use experimental data
obtained via various tandem MS techniques to determine IRs and is self-reproducing.
Unlike IRMS, which relies on high-resolution MS with a magnetic sector as the primary
mass analyzer, FIRMS can be coupled with multiple types of mass spectrometers.
The tandem MS technologies amenable for FIRMS include ion-trap, quadrupole
ion-trap, triple quadrupole and quadrupole time-of-flight. The experimental data collected
via these techniques are analyzed using a non-linear mathematical model describing the
probability of compound fragmentation to extract IRs of locations of individual atoms or
⃑⃑⃑⃑ =
group of atoms within the molecule. Mathematically, the model is of the form c(𝒙)
⃑⃑⃑⃑⃑⃑ ∶ ℝ𝒏 → ℝ are composite or multi⃑ )𝑪𝒂𝒍𝒄𝒖𝒍𝒂𝒕𝒆𝒅 − 𝒇(𝒙
⃑ )𝑬𝒙𝒑𝒆𝒓𝒊𝒎𝒆𝒏𝒕𝒂𝒍 |: Where 𝒄(𝒙)
|𝒇(𝒙
objective functions (MOF) mapped on a vector space (given n is an integer) with 𝛀 ⊆
ℝ𝒏 as the feasible region, subject to constraints. The isotope abundance fractions are the
variables, 𝒇 𝑪𝒂𝒍𝒄𝒖𝒍𝒂𝒕𝒆𝒅 is a polynomial function of nth order mapped in a vector space, and
𝑓𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 is a constant calculated from the experimental data. FIRMS’s non-linear
solver determines isotope ratios through an optimization process with minimization of
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⃑⃑⃑⃑⃑⃑ , a composite or sum of several single objective functions (SOF) multiplied by
𝒄(𝒙)
weighting coefficients.
3.2 Development of FIRMS
3.2.1 Isotope Ratios (IRs)
The evaluation of IRs can help probe the history and source of molecules. For
example, the fixed average global isotope abundances of tertbutyl chloride (C4H9Cl) are
98.93% 12C, and 1.07% 13C.144 However, the isotope ratio of each element of a group of
related tertbutyl chloride molecules is unique and can act like a fingerprint.11 Moreover,
the IR of each atom location can reveal further information to determine the history of a
group of tertbutyl chloride molecules. The IR information can be obtained from mass
spectra using various tandem MS techniques.
3.2.2 Transformation of mass spectra for FIRMS
Fragmentation of a molecule during mass spectrometric analysis produces signals
that correlate to the number of charged molecules of a particular mass-to-charge ratio.
Thus, mass spectral data for a given fragment can be associated to isotope ratios. For
example, the typical isotope ratio of 37Cl/35Cl, 0.35, is commonly used to evaluate mass
fragments for the presence of chlorine. Figure 3.1A shows a simplified mass spectrum of
tertbutyl chloride. The inset shows a close up of the m/z ratios associated with the
isotopes of the molecular ion (i.e., 77, 78 and 79 m/z). The ratio of the abundance of the
79/77 m/z ions, approximately 0.35, supports the presence of chlorine in the molecular
ion. When evaluating the entire mass spectrum of a molecule, the ratio between separate
fragments is not solely due to differences in isotope ratios. It is also due to a number of
factors, including differences in fragmentation efficiency and sensitivity of the detector
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for individual fragments. Because most of these factors cannot be accurately estimated,
isotope ratios cannot be calculated by this type of mass spectrum alone (i.e., the mass
spectrum produced from fragmentation and mass filtering once each, referred to as a
precursor ion scan when using tandem mass spectrometry). Fortunately, tandem mass
spectrometry offers the ability to fragment and mass filter molecules twice, which allows
the ability to gather information as to the fragmentation efficiency and the sensitivity of
fragments relative to each other under a particular set of conditions. When the
fragmentation and sensitivity are consistent, the product scans of isotopes (e.g., 77, 78,
and 79 m/z; Figures 3.1B-D, respectively) should only differ based on the isotopic
makeup of the molecular ion or fragment. Therefore, a series of mathematical equations
can be derived that relates the relative ion abundances to the isotope ratios. This is done
using the product ion scan of a molecular ion or a fragment (e.g., 77 m/z in Figure 3.1B)
as a “template” and relating the differences in the heavier isomer fragmentation to the
isotope ratios (e.g., 78 and 79 m/z; Figure 3.1C and 3.1D, respectively).
The mathematical equations that define the FIRMS technique are derived by first
transforming the product ions of the base mass spectrum into fractions of the total
abundance via Equation 2,
𝛾

𝛼𝑖 = 𝑇 𝑖 ,
𝑀

(2)

where 𝛼𝑖 is the frequency of occurrence of the fragment of interest 𝑖, 𝛾𝑖 is the abundance
of fragment 𝑖, and 𝑇𝑀 is the sum of abundances of all fragments for the mass of interest,
M. For example, when evaluating 77 m/z (Figure 3.1B) for tertbutyl chloride, 𝛼39 is
calculated by Equation 3,
𝛾

𝛼39 = 𝑇39 .
77

(3)
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Figure 3.1. Simplified tandem mass spectral data for t-butyl chloride (2-chloro-2methylpropane) obtained from a GC-MS-MS. A) Precursor ion scan (Q3-scan) of t-butyl
chloride with the molecular ion region magnified in the inset. B) Product ion scan of m/z
= 77. C) Product ion scan of m/z = 78. D) Product ion scan of m/z = 79. The differences
between the product ion scan of the base mass (m/z = 77; B) and the heavier stable
isotopes (m/z = 78 and 79; C and D, respectively) can be attributed to the isotope ratios of
the atoms involved. The difference between the precursor ion scan (A) and the product
ion scan of 77 (B) is due to the differences in ionization processes responsible for
fragmentation.
The  values are the “template” to which all the heavier isotope fragmentations are
related. The same transformation process is then performed on the heavier stable isotope
product ion scans, with a mass of 𝑚 and the frequency of occurrence now represented by
𝜇𝑖 , as shown in Equation 4.
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𝜇𝑖,𝑚 =

𝛾𝑖,𝑚
𝑇𝑚

.

(4)

3.2.3 Isotope ratio calculation
Fragmentation patterns observed in mass spectra occur when a molecule
fragments into smaller pieces. The fragmentation patterns of each heavier stable isotope
(i.e., the 𝜇s) can be related by the base mass (M) fragmentation pattern (i.e., the 𝛼s) and
the isotope ratios of the atoms which make up the heavier isotopes. Therefore, 𝜇𝑖,𝑚 can
also be written in terms of Equation 5, with each isotope ratio product series calculated
by Equation 6.
𝜇𝑖,𝑚 =

𝛼𝑖,𝑀 ∑𝑥
𝑗=1 𝜎𝑗,𝑖,𝑚
𝑦

(5)

𝜎𝑗,𝑖,𝑚 = ∏𝐸𝑒=1 ∏𝐴𝑎=1 𝑓𝑒,𝑎

(6)

∑𝑘=1 𝜎𝑘,𝑚

where 𝜎𝑗,𝑖,𝑚 is the isotope ratio product series function corresponding to the precursor ion
of interest (𝑚), where 𝑥 is the number of possible molecular ions or fragments, with mass
m, potentially contributing to the mass fragment of interest (𝑖). The 𝜎𝑘,𝑚 is the isotope
ratio product series function corresponding to all possible isotopes with mass 𝑚, where 𝑦
is the number of possible molecular ions/fragments with the m/z of the precursor ion of
interest (𝑚). 𝑓𝑒,𝑎 is the isotope ratio of an individual atom, a, of element, e, in the
fragment of interest (𝑖), fragmented from the precursor ion of interest (𝑚), with E as the
total number of elements and A as the total number of atoms of element e associated with
the precursor ion of interest (𝑚).
Equations 5 and 6 are original and can be used to predict the intensities of the
product ions from the stable isotopes of interest, typically M+1, M+2, etc. For example,
the frequency of occurrence for fragments 39 and 40 m/z in Figure 1C can be written as
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Equation 7 and 8, respectively, and the isotope ratio product series function for
13 12

C C21H635Cl, which contributes to 𝜇40,78, is represented by Equation 8.
𝜇39,78 =

𝜇40,78 =

𝛼39,77 [3(𝜎12𝐶 2𝐻1𝐻 35𝐶𝑙 )]
3
5
3(𝜎13𝐶 12𝐶 1𝐻 35𝐶𝑙 ) + 6(𝜎12𝐶 2𝐻 1𝐻 35𝐶𝑙 )
6
2
3
5

𝛼39,77 [3(𝜎13𝐶 12𝐶 1𝐻 35𝐶𝑙 ) + 3(𝜎12𝐶 2𝐻 1𝐻 35𝐶𝑙 )]
6
2
3
5
3(𝜎13𝐶 12𝐶 1𝐻 35𝐶𝑙 ) + 6(𝜎12𝐶 2𝐻1𝐻 35𝐶𝑙 )
6
2
3
5

2
𝜎13𝐶 12𝐶2 1𝐻6 35𝐶𝑙,40,78 = 𝑓13𝐶 𝑓12
𝑓6 𝑓
𝐶 1𝐻 35𝐶𝑙

(7)

(8)
(9)

The coefficients 3 and 6 in Equations 7 and 8 represent the number of possible isotopic
combinations of atoms involved which would lead to a fragment with a mass of 78 m/z
and product ion of 39 m/z. Equations 7 and 8 are actually a simplification of the FIRMS
model in which the isotope ratios of each element are calculated in aggregate (i.e., only
one 13C/12C ratio is calculated for the entire molecule). In the full FIRMS model, the
isotope ratio of each atom location is calculated individually. This is important for
accuracy of the calculated isotope ratios since, in some situations, only specific atoms
may contribute to certain fragments.
For very simple molecules, explicit solutions may be found if another independent
equation is available. Fortunately, another equation that relates the total abundance of the
base mass to the abundance of the heavier isotope fragment or molecular ion can be
written as Equation 10, with 𝑇𝑐,𝑚 and 𝑇𝑐,𝑀 experimentally available by adding all the
abundances of fragments in the mass spectrum of 𝑚 and 𝑀 m/z, respectively.
𝑇

𝑅𝑚/𝑀 = 𝑇𝑐,𝑚 =
𝑐,𝑀

𝑦

∑𝑘=1 𝜎𝑘,𝑚
∑𝑧𝑙=1 𝜎𝑙,𝑀

(10)
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where 𝑅𝑚/𝑀 is the ratio of the sum of 𝜎s that make up the masses 𝑚 and 𝑀, and 𝑧 is the
number of possible molecular ions or fragments with the m/z of the base mass of interest
(𝑀).
3.2.4 FIRMS IRs theorem
It is important that the general proposition of IR calculations by FIRMS be
reasonably proved with a logical demonstration that they will predict correct IRs. If the
predicted IRs model is accurate, FIRMS functions will accurately calculate isotope
abundances with very good accuracy. The proof of FIRMS IRs theorem must follow the
logical true statement that says:
For the isotope ratio calculations, the sum of FIRMS 𝜇s must be one, because the
sum of experimental µ(s) is one.
To test this statement, let us consider Equation 4, which if true, mass the sum of
all experimental s must be one. Thus, the sum of calculated s from the FIRMS model
in Equation 4 must also be one. Consider three fragments 39, 41 and 61 m/z for tert-butyl
chloride in Figure 3.1B as the only fragments used to calculate s and IRs. The paired
data (i.e., the product ions m and m+1 m/z) for calculating s will be 39 and 40 m/z, 41
and 42 m/z, and 61 and 62 m/z (Figure 3.1C). The logical proof is evaluated using 5 steps
below as in Table 3.1.
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Table 3.1. Calculation of µ(s) using Equations 5 for tertbutyl chloride
µ(s)

Equation

𝜇39,78

𝛼39,77 [3 (𝜎12𝐶3 2𝐻1𝐻5 35𝐶𝑙 )]
3 (𝜎13𝐶 12𝐶2 1𝐻6 35𝐶𝑙 ) + 6 (𝜎12𝐶3 2𝐻1𝐻5 35𝐶𝑙 )

𝜇40,78

𝛼39,77 [3 (𝜎13𝐶 12𝐶2 1𝐻6 35𝐶𝑙 ) + 3 (𝜎12𝐶3 2𝐻1𝐻5 35𝐶𝑙 )]
3 (𝜎13𝐶 12𝐶2 1𝐻6 35𝐶𝑙 ) + 6 (𝜎12𝐶3 2𝐻1𝐻5 35𝐶𝑙 )

𝜇41,78

𝛼41,77 (𝜎12𝐶3 2𝐻1𝐻5 35𝐶𝑙 )
3 (𝜎13𝐶 12𝐶2 1𝐻6 35𝐶𝑙 ) + 6 (𝜎12𝐶3 2𝐻1𝐻5 35𝐶𝑙 )

𝜇42,78

𝛼41,77 [3 (𝜎13𝐶 12𝐶2 1𝐻6 35𝐶𝑙 ) + 5 (𝜎12𝐶3 2𝐻1𝐻5 35𝐶𝑙 )]
3 (𝜎13𝐶 12𝐶2 1𝐻6 35𝐶𝑙 ) + 6 (𝜎12𝐶3 2𝐻1𝐻5 35𝐶𝑙 )

𝜇61,78

𝛼61,77 [(𝜎13𝐶 12𝐶2 1𝐻6 35𝐶𝑙 ) + 3 (𝜎12𝐶3 2𝐻1𝐻5 35𝐶𝑙 )]
3 (𝜎13𝐶 12𝐶2 1𝐻6 35𝐶𝑙 ) + 6 (𝜎12𝐶3 2𝐻1𝐻5 35𝐶𝑙 )

𝜇62,78

𝛼61,77 [2 (𝜎13𝐶 12𝐶2 1𝐻6 35𝐶𝑙 ) + 3 (𝜎12𝐶3 2𝐻1𝐻5 35𝐶𝑙 )]
3 (𝜎13𝐶 12𝐶2 1𝐻6 35𝐶𝑙 ) + 6 (𝜎12𝐶3 2𝐻1𝐻5 35𝐶𝑙 )

Step 1: Calculate s.
Step 2: Determine sum of s given by 𝜇39,78 + 𝜇40,78 + 𝜇41,78 + 𝜇42,78 + 𝜇61,78 + 𝜇62,78
and also calculated as follows:

Step 3: Simplify 𝜇39,78 + 𝜇40,78 + 𝜇41,78 + 𝜇42,78 + 𝜇61,78 + 𝜇62,78
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3 (𝜎13𝐶 12𝐶2 1𝐻6 35𝐶𝑙 ) {𝛼39,77 + 𝛼41,77 + 𝛼61,77 } + 6 (𝜎12𝐶3 2𝐻1𝐻5 35𝐶𝑙 ) {𝛼39,77 + 𝛼41,77 + 𝛼61,77 }
3 (𝜎13𝐶 12𝐶2 1𝐻6 35𝐶𝑙 ) + 6 (𝜎12𝐶3 2𝐻1𝐻5 35𝐶𝑙 )

Step 4: Given that 𝛼39,77 + 𝛼41,77 + 𝛼61,77 = 1, simplify step 3 further to the following
fractions.
3 (𝜎13𝐶 12𝐶2 1𝐻6 35𝐶𝑙 ) ∗ 1 + 6 (𝜎12𝐶3 2𝐻1𝐻5 35𝐶𝑙 ) ∗ 1
3 (𝜎13𝐶 12𝐶2 1𝐻6 35𝐶𝑙 ) + 6 (𝜎12𝐶3 2𝐻1𝐻5 35𝐶𝑙 )
3 (𝜎13𝐶 12𝐶2 1𝐻6 35𝐶𝑙 ) + 6 (𝜎12𝐶3 2𝐻1𝐻5 35𝐶𝑙 )
3 (𝜎13𝐶 12𝐶2 1𝐻6 35𝐶𝑙 ) + 6 (𝜎12𝐶3 2𝐻1𝐻5 35𝐶𝑙 )

Step 5: Simplify the numerator and denominator, which gives a solution of 1.

The calculations in Table 3.1 show that the model predicted by FIRMS isotope
ratios calculations is accurate for tert-butyl chloride. For all FIRMS molecules, the
theorem stands to be true as the sum of µs are found to be one for the paired isotope data
for precursor ion M+1 and precursor ions M+2. However, the M+2 µs must include all
the three product ions m, m+1, and m+2 m/z.
3.2.5 Analytical solvers
As alluded to earlier, the calculation of IRs using FIRMS method relies on the
ability of nonlinear solvers to optimize solutions from composite MOFs for isotope
frequencies, a process known as a multi-objective optimization (MOO). The MOF,
⃑⃑⃑⃑ = |𝑓(𝑥)𝐶𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 − 𝑓(𝑥)𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 | is the sum of single objective functions
c(𝑥)
(SOF) multiplied by weighting factors. The calculated abundance functions described by
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Equations 5 and 6 are nth order nonlinear polynomial functions that are also
differentiable. The terms and variables of these equations depend on the number of atoms
present in a fragment. The number of equations computed depends on the number of
fragments considered for a particular FIRMS model. In all circumstances, the models
created by FIRMS are complex because there are at least two atoms of the same
elements, such as carbon and hydrogen that creates largely complex polynomials. Thus,
solving for the isotope abundances of IRs of each atom location in molecules that have
more than two atoms is analytically difficult, and can take an unpredictable amount of
time without finding solutions.
However, the numerical solving approach offers relief for the analysis of the
complex FIRMS models. Because FIRMS models are described by a complex nth order
polynomial and differential functions, numerical solvers offer an incredible advantage
over analytical solving because they are fast, accurate, and may be the only available
method to solve the complex nonlinear problem produced by FIRMS.
In the numerical solver approach, the calculated and experimental 𝜇𝑖 𝑠 (Equation 5
⃑⃑⃑⃑ . The numerical solver minimizes the objective
and 6) are compared via a MOF, 𝑐 (𝑥)
function by evaluating the fractional abundances of all atoms in a molecule that gives
satisfactory solutions. The solutions are comprised of fractional abundance values of the
atoms present in the compound.
3.2.6 Numerical Solvers
There are three categories of analytical solvers, namely simulation, optimization,
and data mining that perform computations and numerical modeling. A computer model
such as a simulation model is a theoretical or a simplified representation of a real-world
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complex system that can be conceptualized. It is designed to show important features and
characteristics of the complex system which is being studied and analyzed. It can provide
meaningful understanding, predictions, and solutions to the problems investigated in the
real system. A significant percentage of a model often represents the actual system.145
Optimization involves finding the maxima or minima of mathematical functions
sometimes subjected to constraints.146 Simulation optimization automatically finds the
best solution of one or several variables that can be controlled. Optimization allows
researchers to make better choices when all data are available. Simulation enables
researchers to understand the possible results of decisions they do not have control over,
considering a range of possible outcomes that are uncontrollable in any model.145-146 Data
mining, on the other hand, is a process of obtaining implicit, formerly unknown and
possibly important patterns and relationships from data.147
3.2.7 Simulation optimization solvers
For FIRMS analysis, coupling simulation and optimization solver is valuable
because simulation replicates the structure of a molecule and the fragments that result
from subjecting a compound through MS analysis, while optimization minimizes FIRMS
MOF to determine the actual values of isotope frequencies subject to constraints. This
process is known as the multi-objective optimization (MOO).
3.2.7.1 Overview of the MOO formulation
Solving a MOO problem constitutes one major challenge i.e., finding a solution
that is acceptable to all MOF. The MOF solution can be calculated through single
objective optimization (SOO) (i.e., optimization of a composite objective function of all
the MOF) or multiobjective optimization (MOO).

35

36
A general single-objective optimization problem is described as:
minimizing (or maximizing) 𝒇(𝒙) subject to 𝒈𝒊 (𝒙) ≤ 𝟎, 𝒊 = {𝟏, . . . , 𝒎} and
𝒉𝒋 (𝒙) = 𝟎, 𝒋 = {𝟏, … , 𝒑} 𝒙 ∈ 𝛀. A solution minimizes or maximizes the scalar 𝒇(𝒙)
given 𝒙 is a n-dimensional decision variable vector 𝒙 = (𝒙𝟏 , … , 𝒙𝒏 ) in a space Ω.
Notice that 𝑔𝑖 (𝑥) ≤ 0 and ℎ𝑗 (𝑥) = 0 represents constraints that must be fulfilled while
performing optimization. Ω is a space that contains all possible x values that can satisfy
the function 𝑓(𝑥) and constraints, where 𝑥 can also be a continuous or discrete vector and
𝑓(𝑥) can as well be continuous or discrete.148
The multiobjective optimization problem (MOO) is defined as:
“a vector of decision variables which satisfies constraints and optimizes a vector function
whose elements represents the objective functions. These functions form a mathematical
description of performance criteria which are usually in conflict with each other. Hence,
the term “optimize” means finding such a solution which would give the values of all the
objective functions acceptable to the decision maker.”148
The mathematical formulation of MOO is
𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒 𝒇𝒊 (𝒙)
} (11)
𝑠𝑢𝑏𝑗𝑒𝑐𝑡 𝑡𝑜 𝒙 ∈ 𝛀 = [𝒙 ∈ ℝ𝒏 , 𝑔𝑗 (𝒙) ≥ 0, 𝑗 = 1, 2, . . . , 𝑚]
where
𝒙 = [𝒙𝟏 , 𝒙𝟐 , . . . , 𝒙𝒏 ]𝑻
𝒇𝒊 (𝒙) = [𝒇𝟏 (𝒙), 𝒇𝟐 (𝒙), . . . , 𝒇𝒌 (𝒙)],
k is the number of objective functions, Ω is the decision space, 𝑥 ∈ Ω is the decision
vector, m is the number of constraints, and Ω ⊆ ℝ𝑛 is the feasible region.149-150
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In the SOO problem, the optimum solution minimizes the composite or SOF 𝑓𝑖 (𝑥)
subject to constraints. However, defining a minimum point for MOO at which all
components of the objective function vector 𝒇𝒊 (𝒙) are simultaneously minimized is
practically implausible because a “utopia” point that can achieve that goal is rarely
possible. Thus, a solution for Equation 11 is always unclear, because there is not a single
unique point that can minimize all MOF simultaneously. This unique problem, therefore,
gives rise to the search for optimality. It is different from solving a scalar optimization
problem and requires finding optimum solutions to the vector MOO. In reality, there are
infinitely many optimal solutions. An optimal solution exists where there are no other
feasible solutions that can improve the value of a SOF without worsening the values of
other objective functions. Therefore, there is not one unique solution; however, there are
a set of pareto solutions found through the use of Pareto Optimality Theory. The theory
argues that 𝑥 ∗ is Pareto optimal if there exists no feasible vector 𝑥 which will reduce
some criterion without increasing simultaneously at least another criterion for
minimization process.148 Thus, Pareto optimal solutions have the characteristics that are
required to find solutions for the vector MOO problem.149-152
Pareto optimality was first proposed by Edgeworth and Pareto and is defined as
follows,153
(1). A vector 𝒖 = (𝒖𝟏 , 𝒖𝟐 , . . . , 𝒖𝒎 ) is described as dominant over another vector
𝒗 = (𝒗𝟏 , . . . , 𝒗𝒎 ), represented as 𝒖 < 𝒗, if 𝒇∀𝒊 ∈ {𝟏, . . . , 𝒎}, 𝒖𝒊 ≤ 𝒗𝒊 and 𝒖 ≠ 𝒗.
(2). Mathematically, a decision vector 𝒙∗ ∈ 𝛀 is Pareto optimal if there is no
another existing 𝒙 ∈ 𝛀 such that 𝒇𝒊 (𝒙) ≤ 𝒇𝒊 (𝒙∗ ) ∀𝒊 = 𝟏, . . . , 𝒌 and 𝒇𝒋 (𝒙) < 𝒇𝒋 (𝒙∗ ) for
at least one value of 𝑗.
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The definition can be interpreted to mean that Pareto solutions exist only if a
solution point cannot be moved from one point to the other without negatively affecting
other objective functions. A solution point is also a weak optimal point if it is impossible
to move the point and improve all objective functions simultaneously.150 The vector of
the objective function is only Pareto optimal if the corresponding decision vector x is
Pareto optimal.149-150
A solution for a specific MOO formulation is sufficient for Pareto optimality,
because it captures all SOF; thus, the method that establishes the solution is significant.
But, it also undermines the objectivity of SOO because the formulation that provides the
necessary conditions for a Pareto optimal point is a solution for that specific formulation
and cannot be applied on a single SOO. In some cases, the solution for a specific
formulation might not be Pareto optimal, or with sufficient conditions, it will always be
Pareto optimal that does not capture all of the Pareto optimal points.150 Therefore,
decisions are often made to allow one of the problem solving processes, either MOO or
SOO, depending on the objective of the decision maker. At no point can the two MOO or
SOO be allowed to find a solution for the same problem.
There are infinite Pareto optimal solutions for the MOO problem. Thus, user
preference for specific or various objective functions is valuable in order to find a single
solution. Given methods that include a priori articulation of preferences, users can
specify preferences before running an optimization algorithm that determines a single
solution suitable to the user preferences. There are other cases where users do not specify
prior preferences but select a single solution from a representation of the Pareto optimal
set, a process known as a posteriori articulation of preferences.150 However, for FIRMS
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analysis, a weighted sum method for a priori articulation preference is used. Weighted
sum method (WSM) allows the MOO problem to be cast as a single-objective
mathematical optimization problem.149-150
Using the WSM to solve the problem represented by Equation 11 involves
selecting scalar weights 𝑤𝑖 and minimizing the general composite reformulated Equation
11 as the objective function represented as:
𝐦𝐢𝐧 ∑𝒌𝒊=𝟏 𝒘𝒊 𝒇𝒊 (𝒙)

(12)

𝒔. 𝒕 𝒙 𝝐 𝛀,
where 𝒘𝒊 ≥ 𝟎, ∀𝒊 = 𝟏, . . . , 𝒌 and ∑𝒌𝒊=𝟏 𝒘𝒊 = 𝟏 under convexity assumptions.149 All the
positive weights are assumed to minimize Equation 12 and provides the necessary
conditions for Pareto optimality which means that the minimum of Equation 12 is always
Pareto optimal.154-155
3.2.7.2 Normalization in the WSM
Ideally, the scalar weights of each SOF are assigned by the decision maker (DM)
or user based on the deep-rooted knowledge of the problem at hand. But because
different SOF can have different magnitude, the normalization of the SOF is necessary to
find a Pareto optimal solution consistent with the scalar weights assigned by the FIRMS
user. Thus, the scalar weights are calculated as:
𝒘𝒊 = 𝒖𝒊 𝜽𝒊 ,

(13)

where 𝒖𝒊 are the weights assigned by the user and 𝜽𝒊 are the normalization factors.149
There are many ways of determining normalization factors, such as:
▪

normalization by the degree of the objective function at the initial point 𝑥0 , where
𝟏

𝜽𝒊 = 𝒇 (𝒙 );
𝒊

𝟎
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▪

𝟏

normalization using the minimum of the objective functions, 𝜽𝒊 = 𝒇 (𝒙[𝒊] ) where
𝒊

𝒙[𝒊] solves 𝐦𝐢𝐧{𝒇𝒊 (𝒙) 𝒙: 𝒙 ∈ 𝛀 };
𝒙

▪

normalization by the difference between optimal function values evaluated in the
Nadir and Utopia points which gives the length of the intervals where the ideal
objective function varies within the Pareto optimal set.149

The first two normalization schemas are ineffective and impractical because the
initial point, 𝑥0 , does not provide accurate representation of the function behavior at
optimality. 𝑓𝑖 (𝑥0 ) equal to zero cannot be used, and using optimal solutions to individual
objective functions can distort the scaling because optimal values are not associated with
the geometry of the Pareto set.149
In the third normalization scheme, it is easy to determine the ranges of the
objective Pareto optimal set which provides incredible information for the solution
process. The initial step is to determine 𝒛∗𝒊 = 𝒇𝒊 (𝒙[𝒊] ) ∈ 𝓡 values of the ideal objective
vector 𝒛∗ ∈ 𝓡𝒌 by minimizing the individual objective function subject to user-defined
original constraints, i.e.,149
𝒛∗𝒊 = 𝒇𝒊 (𝒙[𝒊] ) where 𝒛∗𝒊 = 𝒂𝒓𝒈 𝐦𝐢𝐧{𝒇𝒊 (𝒙) ∶ 𝒙 ∈ 𝛀}.

(14)

𝒙

Two ideal objective vectors 𝒛𝑼 = 𝒛∗ known as the Utopia point which provides the
lower bounds, and Nadir point 𝒛𝑵 components that define the upper bounds can be
defined for the Pareto optimal set using the ideal vector 𝒛∗ ∈ 𝓡𝒌 . The Nadir point can be
formulated as:
[𝒋]
149
𝒛𝑵
𝒊 = 𝐦𝐚𝐱 (𝒇𝒊 (𝒙 )) , ∀𝒊 = 𝟏, . . . , 𝒌.

(15)

𝟏 ≤𝒋 ≤𝒌
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Using the difference of optimal function for normalization the values for 𝜃𝑖 can be
formulated as,
𝜽𝒊 =

𝟏
𝑼
𝒛𝑵
𝒊 − 𝒛𝒊

.149

(16)

The normalization schema using Nadir and Utopia points provides the best normalization
solution because the objective functions are normalized by the true intervals of their
variations within the Pareto optimal set. Thus, all objective functions normalized are
bounded by
𝒇𝒊 (𝒙) −𝒛𝑼
𝒊

𝟎 ≤

𝑼
𝒛𝑵
𝒊 − 𝒛𝒊

≤ 𝟏,

(17)

which gives equal magnitude to each objective function.149
In practice, Nadir and Utopia points can be estimated without finding solutions
for any optimization problem, rather by evaluating random sampling points x subjected to
user-defined constraints. For FIRMS, the points were calculated as maximum and
minimum of each objective function evaluated at the upper and lower boundaries defined
by the user.149
The sub weights, 𝑢𝑖 , are assigned by the user; for example the Ranking Sum (RS)
method. In this method, the sub weights are the individual ranks normalized by dividing
the sum of the ranks. The RS function is formulated as follows:156
𝒌− 𝒓𝒊 +𝟏
𝒌
∑𝒋=𝟏 𝒌− 𝒓𝒋 +𝟏

𝒖𝒊 =

(18)

where k is the total number of objective functions, 𝑟𝑖 is the rank of the ith objective
function and 𝑖 𝑡ℎ = 1, 2, . . . , 𝑛.156
Equation 18 can be further be written as:
𝜇𝑖 =

2(𝑘+1−𝑟𝑖 )
𝑘(𝑘+1)

.

(19)
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The WSM has a major weakness for linear objective functions and linear
problems that use simplex-type methods to find solutions for weighted sum functions.
Because, for any linear function, the simplex method evaluates the vertex to find
solutions and ignores the weights that can yield solutions in the interior of the linear face
of Pareto optimal set. This problem is known to have optimality issues, and the vertex
solutions on the Pareto optimal set are not practically valuable solutions. An optimal
solution might also experience enormous jumps when there is a slight change in weights
but will not experience the same jumps when there are broad changes in weights, a
problem known as sensitivity issues. However, the probability of encountering the same
problems with non-linear functions is very low. Because, for example, for polynomial
objective functions, the efficient frontier of the Pareto optimal is non-linear. And one of
the ways to overcome linearity of Pareto face is to convert the objective functions into
polynomials; for example, converting them to quadratics by squaring the functions.149
Fortunately, FIRMS functions are not prone to WSM problems since they are all
polynomials (nonlinear). Moreover, FIRMS functions are further classified as non-linear
(nth order polynomials and multi-variable differential functions), non-convex and nonsmooth functions. This classification was very significant in selecting the simulation
optimization algorithms for MOO problems. Thus, understanding nonlinear, nonconvex
and nonsmooth functions, and how to apply this knowledge to FIRMS, is fundamentally
important.
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3.2.8 Nth order polynomial and multi-variable differential functions
Polynomials include 𝑓(𝑥) functions, such as quadratic, cubic, quartic and
functions with nonnegative integer powers of x. A polynomial of a degree n is a function
of the general form157
𝑓(𝑥) = 𝑎𝑛 𝑥 𝑛 + 𝑎𝑛−1 𝑥 𝑛−1 +. . . +𝑎2 𝑥 2 + 𝑎1 𝑥 + 𝑎0

(20)

where the a(s) are real numbers also known as coefficients of the polynomial.
From the general formula, an example function of n = 4, such as modified Ferrari
equation, can be formulated as, 158-159
𝑓(𝑥) = 𝑥 4 + 𝑥 3 − 6𝑥 2 − 6𝑥 + 36

(21)

The function in Equation 19 is also known as a quartic polynomial, 157 and has a graph
shown below.

Figure 3.2. 3D plot of a 4th degree polynomial function represented by Equation 21.

A differential function contains term(s) involving derivatives of the dependent
variable, y with respect to independent variable, x. The solutions for differential
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equations are functions. For example, Equation 22 shows a simple differential
function.160-163
𝑑𝑦
d𝑥

= 4𝑥 3 + 3𝑥 2 − 12𝑥 − 6

(22)

The functions are characteristics of the relationship between a continuous variable and its
rate of change. Differential equations are widely used in applications such as FIRMS for
Chemistry, Physics, Biology, Economics, Engineering, and other areas of natural
science160-163. The functions represented by the FIRMS model are both polynomials and
differential because there is at least a 2nd degree term in all equations.
3.2.9 Isotope combinations and data structure algorithms
FIRMS Equations 5 and 6 are both nth degree polynomials and are differentiable.
When expanded a specific example, such as tertbutyl chloride, the functions become
Equations 7, 8 and 9. These equations represent complex polynomial functions with
several independent variables. The degree of the polynomials depends on the number of
atoms of individual elements (e.g., C, O, and H), n, where n = 1, 2, 3, 4, etc. Thus, unlike
general polynomial function described in Equations 11 and 12 above, the terms and
coefficients of FIRMS functions are independent of each other and only dependent on the
atoms present in that term. The coefficients of each term also depend on the probability
of occurrence of product ion in the molecular fragmentation pattern. For example, given
Equation 8, the numerator has two terms, each of which have a coefficient of 3, meaning
that the fragment obtained by changing an isotope of carbon or hydrogen for m/z 40 can
only occur three times for both elements. Meanwhile, in the denominator, the coefficient
of the first term is 3, while for the second term it is 6. For the precursor ion in question,
there are 3 accepted molecule combinations that can be formed by changing an isotope of

44

45
carbon, while there are 6 possible molecule combinations that can be formed by replacing
a hydrogen atom with a deuterium atom.
Determining the possible combinations of atoms which make up a particular
fragment leading to a polynomial function, can be complicated. Using the general laws of
permutations, it can be shown that the number of possible combinations increases
exponentially, depending on the number of atoms in a molecule. For example, potential
combinations of tertbutyl chloride molecules with the chemical formula C4H9Cl that can
occur by changing an isotope by mass of 1 is equivalent to 213 (i.e., the number of carbon
and hydrogen atoms as the power) which gives 16384 possible combinations. However,
the number of utilized combinations is 3 for carbon and 6 for hydrogen. Therefore,
producing 213 combinations and filtering out unwanted combinations to form FIRMS
polynomial equations is a complex task that requires specialized data structure
algorithms.
There are many different types of data structures, in which data are arranged
sequentially. Data structures have logical starts, and logical ends, with elements
embedded in them, and are used to store and organize data. The choice of data structure
depends on several factors, such as what needs to be stored, the cost of frequently
performed operations, computer memory usage, and the ease of implementation.164
We developed two types of data structures algorithms for FIRMS, tree (for nonlinear functions) and stack (for linear functions), and their performance was tested with
FIRMS models. Even though FIRMS functions are non-linear, the linear stack data
structure easily produced the combinations of atoms for the molecular fragments of
interest. A tree is a type of data structure often used to represent hierarchal data. For
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example, in a company, sits the chief executive officer (CEO) at the top, with two
deputies (i.e., president and chief technology officer (CTO)) who also have deputies
called managers. Below the managers are the supervisors who oversee workers. The
company, therefore, can be described by a tree. A logical model of a tree can be
represented such that the top hierarchy is the root, and from the root there are branches
(inverted tree diagram). In computational modeling, the tree is a non-linear collection of
entities called nodes linked together to simulate a hierarchy. In each node, beginning with
the root, there can be different types of data (integer, character, or string) stored in the
node and may contain some reference to some other nodes, also known as “children.” In
the tree diagram, the only direction used is from the top (root) to the bottom, or from
ancestors to descendants (grandchildren). A tree can be a recursive data structure if it
contains a distinguished root and subtrees in which the arrangement is such that root of
the tree contains links to root of the subtrees. A tree with N nodes can have only N-1
links or edges represented by an arrow. The depth of x in a tree is defined as the length of
the path from the root to node x, or the number of edges in the path from root to x. The
height of a node entry is defined as the number of edges in the longest path from x to a
leaf node or height of a root node. A leaf node is a node without linked nodes compared
to other nodes. The height and depth of a tree are two different properties and may or
may not be the same. A tree data structure may be binary, with nodes that have a
maximum of two edges.165-166 Figure 3.3 shows an example of tree (binary) data structure
for BrO3.
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Figure 3.3. A tree diagram of BrO3 with tree depth four.

The root of the tree (BrO3 with a molecular mass (M) of 129 m/z) represents a
molecular ion mass of M+2. From the root, each node is occupied by atoms in the
molecule. The first level (parents) shows 81Br picking up 18O (left child) and 16O (right
child), or 79Br (right branch doing the same. The second level in the tree shows the
molecule picking up 18O and 16O for each of the first offspring (first children). The
integers over the nodes represent the remaining mass after picking an atom, or a “child.”
For example, starting with 129 m/z at the root and following the left branch with 81Br, the
mass remaining is 48 (i.e., 129-81). While on the other side, the right path gives a
remainder of 50 (i.e., 129-79). These processes continue from the first to the third
oxygen. Notably, in the tree diagram, some paths discontinue before making the target
molecule BrO3. Also, some paths in the diagram have all four atoms; however, there is
still mass remaining. Therefore, the combination is also not valid. For the two scenarios,
the combinations are pruned. This tree diagram has a tree depth of 4. The pruning can be
carried further, as shown in Figure 3.4.
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Figure 3.4. Represents a pruning process of a tree diagram of BrO3 with tree depth four

Other examples of tree diagrams for FIRMS include dichloromethane (DCM)
(Figure 3.5), and folic acid (Figure 3.6). For DCM, shown in Figure 3.5, with CH2Cl2,
there are 3 elements, each with 2 isotopes giving a total of 6 atoms. This is tree depth of 6
which gives combinations of 26, or 64.

48

49

Figure 3.5. Represents a tree diagram of dichloromethane (DCM) with a tree depth 6.

The tree data structure for folic acid (C19H19N7O6) is shown in Figure 3.6. In folic
acid molecule, there are 4 elements. Thus, this is a tree depth of 51 which gives
molecular combinations of 251 equivalent to 2.25 x 1015
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Figure 3.6. Represents a tree diagram of folic acid with a tree depth 51.

In the last tree diagram example, sorting the relevant molecule combinations is a
tedious process, and can lead to a high cost in computation time, memory use and the
difficulty of implementation. Thus, another data structure type is desired which does not
have limitations of the tree-type data structure. In this case, a linear data structure, known
as stack, was implemented for FIRMS models.
Stacks are an Abstract Data Type (ADT) that can be logically constructed as a
linear structure that represents a real physical structure, in which insertion and deletion
can be implemented, such as with a deck of cards or a pile of plates. In real applications,
the stack structure allows operations to take place at one end only. For example, plates or
cards can only be removed or added at the top of the pile. This idea is also known as
Last-In-First-Out (LIFO). The argument is that the element added/inserted last, is
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accessed first. Any process that would allow operations from the bottom is eliminated.
The syntax for insertion is known as a push operation, and removing elements is known
as a pop operation. Stack can be implemented using Array, Structure, Pointer, and Linked
List. A stack can be a fixed size or can have the ability to resize which is an important
feature for FIRMS models.
The stack data structure was more advantageous for FIRMS applications, and
thus, replaced the tree data structure for determining isotope combinations that could
produce a particular fragment mass. It gives FIRMS the ability to create a combination of
atoms to produce a molecule and add it into a stack, test if it meets the requirements and
pop out unwanted combinations. Compared to the tree method, this method consumed
less time, required a relatively small amount of memory, and was easy to implement.
Within the FIRMS software, a computer algorithm was built with a function that
was comprised of a string (p) variable list and integers (massDiff) to represent the atomic
mass difference between the base mass M and precursor ion M+1. For example, if p = C3
and massDiff = 1 the two strings of carbon atoms produced by the functions are
12 12 12

C C C and 13C12C12C as shown in Figure 3.7. This idea can be expanded to a

molecule like DCM (CH3Cl2) where the function is called for each element C, H, and Cl
to produce a string of isotopes and the mass difference of interest.
When the individual element lists are created (i.e., C, H, H, H, Cl, Cl) by the
isotope combination algorithm they are pushed on the stack creating the initial state of the
first element in the list as shown in Figure 3.7. Each element list produced in the stack
also has a multiplier embedded in them. The product of the multiplier for the elements in
a string becomes the coefficients of sigma in Equations 5 through 9. When all the atoms
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of the first elements have been added to the second element in the list the last one is
added and inserted into the second stack as shown in Figure 3.8 by the arrows. The
process continues until all elements have been combined and added to the stack as shown
in Figure 3.9. The stack size depends on the number of molecule combinations and can
be N = 1, 2, 3, … k where k is an integer. In the final step, the completed molecular
formula is double checked to make sure it is accurately equal to the required mass
difference, as shown in Figure 3.10. Any undesired molecular formula is eliminated from
the corrected list. At this point the algorithm has enough molecular combinations with
accurate isotopes. These combinations are then passed to Equations 5 and 6 which further
produces Equations 7-9 for isotope abundance calculations through minimization of the
objective function.

C13C12C12
C12C12C12
Figure 3.7. A list of string showing combinations of atom for carbons in stack data
structure.
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Pop
C13C12C12
Combine
C13C12C12H1H1H1
Push

C12C12C12

C13C12C12H1H1H1

Figure 3.8. A string of carbon atoms combining with hydrogen atoms in stack data
structures with molecular formula C3H3

Pop
C12C12C12H2H1H1
Combine
C12C12C12H2H1H1Cl35
C12C12C12H1H1H1

Push

C13C12C12H2H1H1
C13C12C12H1H1H1

C12C12C12H2H1H1Cl35

Figure 3.9. A string of combined carbon, hydrogen and chlorine atoms in a stack data
structure with molecular formula C3H3Cl

Check mass against desired mass

C13C12C12H1H1H1Cl35
C13C12C12H2H1H1Cl35
C12C12C12H1H1H1Cl35

C13C12C12H1H1H1Cl35

C12C12C12H2H1H1Cl35

C12C12C12H2H1H1Cl35
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Figure 3.10. A stack of combined atoms in arranged on top of each other like plates
stack together. The right side are the molecular formulas that have been crossed checked
for accuracy

Another example of the implementation of stack data structure is shown using a
BrO3 molecule. A list is created {Br, O, O, O} for all the atoms in the molecule. Then an
atom string is built up which comprises stable isotopes of each atom. For this example,
79

Br and 81Br are put together on the stack as the first atoms of two possible molecules as

shown in Figure 3.11. The two stable isotopes are popped off the stack and then added to
the stable isotopes of (16O, 17O, 18O), as shown in Figure 3.12. The process (i.e., brute
force) continues until all the stable isotopes of oxygen are added as shown in Figure 3.13.
The brute force method proceeds and eventually produces molecular formulas for all
possible atom combinations. The molecular formulas are cross checked again to eliminate
the unwanted combinations. For a mass difference of 2 (e.g., base mass M+2), the
process can be optimized by keeping a running count of the additional mass as shown in
Figure 3.14. The process continues until the full molecular formula is reached, and all
unwanted combinations that exceed the mass difference are eliminated, as shown in
Figure 3.15. Then the accepted isotope combinations are used to calculate fractions based
on isotope frequency (probability).

Br81
Br79
Figure 3.11. Using 81Br and 79Br atoms to describe stack structures for single atoms.
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O16
Br79

O17
O18
Br79O18
Br79O17
Br79O16
Br81O18
Br81O17
Br81O16

Figure 3.12. A stack structure of BrO molecules describing stack diagram with two
atoms.
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Figure 3.13. A stack structure of BrO3 molecules describing stack diagram of four atoms.
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Br79O17O18

+2

Br79O17O17

Figure 3.14. A stack structure of BrO3 molecules describing stack diagram with three
+1
Br79O17O16
Br79O16
+0
atoms and showing
the elimination
of unwanted structures.
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+3

Br81O16O16O17

+2
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Figure 3.15. A stack structure of BrO3 molecules describing stack diagram with four
atoms and showing the elimination of unwanted structures.

Calculating fractions for isotope combinations produced by stack data structures
can be described as events and involves two methods of addition and multiplication. For
single events, the simple mathematical rule of multiplication is employed. However, if
two events occur randomly with the same outcome but following two different paths, the
probability calculations become complicated. For example, in isotope combinations, two
different fragments might have the same mass, but different molecular ion formulas. The
same outcome, which is the calculated mass, must be determined in two different ways to
represent different paths, e.g., 13C or 2H isotopes that contributes the same change in mass
by one unit. Both isotopes give a change of molecular mass by 1, but the two paths
leading to the mass difference of 1 must be determined independently. In such
circumstance, the probability tree diagram can be invoked which follows the rules of
multiplication of probabilities along the branches (path) and addition of the paths to

56

57
determine the probabilities of independent events following a different path but with the
same outcome. For example, the tree diagram in Figure 3.15, shows two independent
events that would likely lead to the same outcome using independent paths. The
likelihood that Hawi (H) will watch news (NW) when she wakes up can follow two
paths, i.e., Hawi (H) wakes up, drinks coffee (C) and watches news (NW) or Hawi wakes
up, does not drinks coffee (NC) and watches news (NW). The probability that Hawi will
watch news can be then calculated as the sum of P (C n NW) and P (NC n NW) which
results in a value of 0.5 given that there are equal chances of the first two events
occurring, and where P is the probability/likelihood of the event happening. In Figure
3.16, the same probability result of 0.5 can be arrived at using the sum of probabilities P
(C n NNW) and P (NC n NNW). But that cannot be allowed as a solution, since none will
result in Hawi watching the news. And such solutions are thus eliminated from the
overall results using computer algorithms in applications that involve complex analysis
such as FIRMS analysis.
The same knowledge of probability tree diagram is applied in FIRMS to
determine the probability that a particular fragment of M+1 will have a specific
combination of atoms that will produce acceptable results and filter out unwanted
combinations with similar solutions. After adverse combinations are eliminated, the
multiplication and addition rules are applied. Since the frequency (isotope abundance) of
occurrence is known, the probability of atom combinations that produces the mass M+1
can be calculated as multiples of the frequencies raised to the power of the number of
atoms as shown in Equations 5-9. The probabilities of possible combinations that produce
the mass M+1 are then added together (Figure 3.16).
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Figure 3.16. A flow chart of a probability tree diagram showing the path of events.

The isotope combinations produced by the computer algorithm are used to
generate Equations 5-9, which make up the MOF. As described earlier, these functions
have the characteristics of nonlinear functions. Finding a solution for MOF described as
MOO problems requires unique algorithms. Existing computer algorithms for finding
solutions to MOO problems are built for specific types of functions, such as nonlinear,
nonconvex, and nonsmooth functions (NSF), linear, convex and smooth functions, and
nonlinear, convex and smooth functions. Thus, knowledge about the convexity and
smoothness of FIRMS functions is significantly important to select the best solution
algorithm.
3.2.10 Nonconvex, constrained and non-smooth functions (NSF)
A function is defined as nonconvex if it has multiple minima.167 Often,
optimization problems become numerically complex to solve when neither the objective
functions nor constraints have a convexity structure. Constraints are conditions of an
optimization problem that must be satisfied by the optimum solutions.168 A function, f
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geometrically described as f: Rn R is convex if dom f is a convex set and f (x + (1-)
y)   f(x) + (1-) f(y) for all x, y  dom f, 0    1, as shown in Figure 3.17.169

Figure 3.17. A graph describing a geometrical convex function f.

f is concave if –f is convex. f is strictly convex if dom f is convex and f (x + (1 -

) y) <  f(x) + (1-) f(y) for x, y  dom f, x  y, 0 <  < 1.169
A function is described as non-convex if it is neither convex nor concave, and has
wave-like shapes, i.e., troughs and crests. Non-convex functions are often assumed to be
nonsmooth (a function without continuous derivatives within a certain domain) with
several feasible regions, and many locally optimal points within each region described by
a set of boundaries. Since non-convex functions are nonsmooth and discontinuous, the
derivatives are impossible to compute. Hence, the function cannot be described as
increasing or decreasing (i.e., a possible solution does not provide enough information
about a given point that can give enough information).
Of course, the general explanation of a nonconvex and nonsmooth function
cannot explicitly explain the convex properties of FIRMS models. FIRMS functions are
complex and require a different approach to characterize them as nonconvex and
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nonsmooth. The procedure involves using vector and matrices in a given search space
subject to constraints to explain the nonconvex properties of FIRMS functions.
Consider the objective function 𝑐(𝑥): ℝ𝑛 → ℝ subject to constraints described by
vector 𝑔𝑗 : ℝ𝑛 → ℝ for some integer (n) and isotope frequency (i). The function c(x) is
also of the form
𝑐(𝑥) = |𝑓(𝑥)𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 − 𝑓(𝑥)𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 |

(23)

for the vector 𝑥 with isotope abundance frequencies as the variables, 𝑓 is a polynomial
mapping from Rn  R, and 𝑓(𝑥)𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 is a constant calculated from the
experimental data. Both the objective functions and polynomial functions are continuous
with infinite derivatives, with the exception where 𝑓(𝑥)𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 = 𝑓(𝑥 )𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 .
The objective function mapping from ℝ𝑛 → ℝ, which is continuous with 1st and
2nd derivatives can only be convex if it has a positive definite Hessian matrix.170 The
polynomial function 𝑓(𝑥) in Equation 15 is either smooth or nonsmooth and constrained
to the convex n-cell defined by the isotope abundance frequency in 𝑔𝑗 : ℝ𝑛 → ℝ.171-172
Using tert-butyl chloride and the polynomial 𝑓(𝑥), Equation 7 can be formulated as
Equation 24.

𝑓(𝑥, 𝑦, 𝑧) = 6𝜇𝑥 3 𝑦 5 𝑧 − 9𝜇𝑥 3 𝑦 6 𝑧 + 3𝜇𝑥 2 𝑦 6 𝑧 − 3𝛼𝑥 3 𝑦 6 𝑧 − 3𝛼𝑥 3 𝑦 5 𝑧

(24)

where vector 𝑥 = (x, y, z). x, y, and z represent the isotope frequencies for carbon,
hydrogen, and chlorine respectively, and  and  are empirical constants. The Hessian
matrix of Equation 16 can be formulated as
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Η=

𝜕2 𝑓

𝜕2 𝑓

𝜕2 𝑓

𝜕𝑥 2
𝜕2 𝑓

𝜕𝑥 ∂𝑦
𝜕2 𝑓

𝜕𝑥𝜕𝑧
𝜕2 𝑓

𝜕𝑦 ∂𝑥

𝜕𝑦 2

𝜕𝑦𝜕𝑧

𝜕2 𝑓

𝜕2 𝑓

𝜕2 𝑓

[ 𝜕𝑧 ∂x

𝜕𝑧𝜕𝑦

𝜕𝑧 2

(25)
]

Where
𝜕2 𝑓
𝜕𝑥 2

= 36𝜇𝑥𝑦 5 𝑧 − 54𝜇𝑥𝑦 6 𝑧 + 6𝜇𝑦 6 𝑧 − 18𝛼𝑥𝑦 6 𝑧 − 18𝛼𝑥𝑦 5 𝑧

𝜕2 𝑓
𝜕𝑦 ∂𝑥
𝜕2 𝑓
𝜕𝑧 ∂x
𝜕2 𝑓
𝜕𝑦 2

(27)

= 18𝜇𝑥 2 𝑦 5 − 27𝜇𝑥 2 𝑦 6 + 6𝜇𝑥𝑦 6 − 9𝛼𝑥 2 𝑦 6 − 9𝛼𝑥 2 𝑦 5

(28)
(29)

= 90𝜇𝑥 2 𝑦 4 𝑧 − 162𝜇𝑥 2 𝑦 5 𝑧 + 36𝜇𝑥𝑦 5 𝑧 − 54𝛼𝑥 2 𝑦 5 𝑧 − 45𝛼𝑥 2 𝑦 4 𝑧

(30)

= 30𝜇𝑥 3 𝑦 4 − 54𝜇𝑥 3 𝑦 5 + 18𝜇𝑥 2 𝑦 5 − 18𝛼𝑥 3 𝑦 5 − 15𝛼𝑥 3 𝑦 4

(31)

𝜕𝑥 ∂𝑦
𝜕2 𝑓
𝜕𝑧𝜕𝑦

𝜕𝑧 2

= 90𝜇𝑥 2 𝑦 4 𝑧 − 162𝜇𝑥 2 𝑦 5 𝑧 + 36𝜇𝑥𝑦 5 𝑧 − 54𝛼𝑥 2 𝑦 5 𝑧 − 45𝛼𝑥 2 𝑦 4 𝑧

= 120𝜇𝑥 3 𝑦 3 𝑧 − 270𝜇𝑥 3 𝑦 4 𝑧 + 90𝜇𝑥 2 𝑦 4 𝑧 − 90𝛼𝑥 3 𝑦 4 𝑧 − 60𝛼𝑥 3 𝑦 3 𝑧

𝜕2 𝑓

𝜕2 𝑓

(26)

=0

𝜕2 𝑓
𝜕𝑥𝜕𝑧
𝜕2 𝑓
𝜕𝑦𝜕𝑧

(32)

= 18𝜇𝑥 2 𝑦 5 − 27𝜇𝑥 2 𝑦 6 + 6𝜇𝑥𝑦 6 − 9𝛼𝑥 2 𝑦 6 − 9𝛼𝑥 2 𝑦 5

(33)

= 30𝜇𝑥 3 𝑦 4 − 54𝜇𝑥 3 𝑦 5 + 18𝜇𝑥 2 𝑦 5 − 18𝛼𝑥 3 𝑦 5 − 15𝛼𝑥 3 𝑦 4

(34)

But 𝑓(𝑥) is not Hermitian since it is not equal to its conjugate transpose, i.e.,
𝐴𝐻 ≠ 𝐴𝑇̅

(35)

where A is an n x n matrix, AT denotes the transpose of the matrix A, 𝐴̅ denotes the
conjugate matrix, and AH symbolizes the Hermitian which arises from the combined
operation of taking the transpose and complex conjugate of complex matrices.173-174
Additionally, the second leading minor of the matrix in Equation 25 is negative which
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means the matrix is not positive definite. The additive inverse of the matrix also shows
leading minor and second-leading minor which results to nonnegative semidefinite.
These descriptions do not meet the criteria described below:
let A = (𝑎𝑖𝑗 ) be an n x n symmetric matrix and 𝐷𝑘 the determinant for k = 1…, n be the
leading principal minors:
𝑎11
21
𝐷𝑘 = [𝑎…
𝑎𝑘1

𝑎12 … 𝑎1𝑘
𝑎22 … 𝑎2𝑘 ]
…
…
𝑎𝑘2 … 𝑎𝑘𝑘

(36)

Then, A is positive definite if and only if 𝐷𝑘 > 0 for k 1…, n. A is negative definite if
and only if (−1)𝑘 𝐷𝑘 > 0 for k = 1…, n (i.e., if and only if the leading principal minors
alternate in sign beginning with 𝐷1 ). A is positive semidefinite only if all its principal
minors are nonnegative and, A is negative semidefinite only if its kth order principal
minors are nonpositive for k odd and nonnegative for k even.175-176
FIRMS equations were tested against the principles described above to
demonstrate that the matrix in Equation 25 cannot be convex or concave on the nth cell it
is constrained. Thus, the FIRMS polynomial function f(x) in Equations 6 and 7 are
nonconvex, hence, all FIRMS functions are nonconvex.
Additionally, the nonconvex and nonsmooth property of FIRMS functions were
tested using computer algorithms in Analytical Solver SDK Platform acquired from
Frontline Solvers. FIRMS functions showed the presence of many local extrema within
the constrained boundaries, further evidence of nonconvex and nonsmooth functions that
require nonlinear and nonconvex optimization algorithms. Such algorithms perform a
random sampling of all possible solutions to determine the best solutions. These methods
are nondeterministic or stochastic, which means that they might give different results
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with the negligible difference in every analysis. They are entirely dependent on the points
sampled.148
3.2.11 Solver algorithms
There are few known solvers for analyzing nonconvex and nonsmooth nonlinear
models which have the characteristics of multiple feasible regions, multiple local optima
within given regions, discontinuity, nonsmooth behavior, and lack of general information
about the slope or derivatives in the direction of increasing or decreasing function. There
are currently three algorithms for solving nonconvex and non-smooth complex problems
such as FIRMS functions. They are Evolutionary/Genetic Algorithm, Tabu Search and
Scatter Search Algorithms.
3.2.11.1 Evolutionary/Genetic Algorithms (EA/GA)
Mathematical problems have three types of solutions: exact answers or roots,
optimal, or extrema. In the case of optimal and extrema, the best solution is often
determined relative to the problem being analyzed, the solution method, and the accepted
tolerance values. Optimization is the process of altering the input of mathematical
methods to find the minimum or maximum output. The input is comprised of variables,
the mathematical method referred to as an objective function, and the output is the
solution of an optimized objective function.177
In a real physical system where complex nonlinear problems exist and entropy
plays a significant role, it is quite difficult to determine the best solution. Quantum theory
implies that there are infinite dimensions that are different and correspond to decisions
made. A small change in quantum systems can result in complex and random results.
Many systems in the universe appear to replicate quantum systems, or are relatively less
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complex. Thus, the high number of complex systems has demanded the development of
sophisticated solvers. Optimization algorithms were designed as primary tools required to
solve highly complex problems encountered when analyzing nature, and designing or
predicting results.177 As shown in Figure 3.18, there are six categories of optimization
algorithms.

Figure 3.18. Examples of the optimization algorithms.177
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Finding a solution to a problem can be seen as searching through a defined or
non-defined space for possible solutions. Since the main objective is finding “the best”
solution, the task thus bears the characteristics of optimization. For relatively small
search spaces, there are classical methods that are suited for such problems, whereas for
larger spaces, distinctive artificial techniques are used, such as EAs/GAs 177-178
Evolutionary/Genetic algorithms (EA/GA) represent a popular meta-heuristic
optimization and search technique guided by the principles of genetic evolution and
natural selection.159-160 This method was invented by John Holland over a decade
between the 1960s and 1970s. It was later advanced and introduced to research by
Holland’s student, David Goldberg, when he solved a complex problem involving the
control of gas-pipeline transmission for his dissertation research.177
The multi-objective EA has appealed to many researchers because it possesses
many readily apparent advantages. EA can optimize with continuous, or discrete
variables and functions without derivative information. The algorithm performs a
simultaneous search from a broad sampling of the objective function while handling a
large number of variables. EA can couple with parallel computers and optimize variables
with extremely complex objective functions. It provides a list of optimum variables,
performs optimization with encoded variables, addresses discontinuity, can solve
nondifferential and nonconvex problems with multiple peaks, and can acquire the Pareto
front in analysis.151, 177
There are two approaches to solving MOO problems. One involves the use of a
single composite function or optimizing one objective function while the rest are
considered a constraint set. The second optimization approach is to determine the
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complete Pareto optimal solution set or a representative subset. As discussed previously,
Pareto optimal solutions are nondominated with respect to each other. The single
composite function with weighted sum method was applied in the optimization of FIRMS
models.179-180
In EA optimization, a solution vector 𝑥 ∈ Ω is known as an individual or a
chromosome. They are of discrete units called genes. Genes control single or multiple
features of the chromosome. In the original implementation of EA, Holland assumed that
genes were represented by binary digits. However, modern EAs have varied gene types.
Usually, a chromosome relates to a specific solution x in the feasible space. As a result, it
requires mapping mechanisms between the feasible solution space and the chromosomes
which is a process known as encoding.178-179
A collection of chromosomes is known as the population which is initiated
through a random process. During optimization, the search evolves, as does the
population including the fitness functions. The two operators used to generate new
solutions in the EA are the crossover (the most important operator) and mutation. During
crossover two chromosomes known as parents combine to form new chromosomes or
offspring. These parents are selected among the existing chromosome population with
good fitness in order for the offspring to inherit good genes that make them fitted parents.
Through iterative application of the crossover operator, the chromosomes with good
genes survive in the population, which eventually leads to convergence of the optimum
solution.178-179
The function of the mutation operator is to introduce random changes into the
features of chromosomes. Its implementation at gene level is very minute and depends on
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the size of the chromosomes. Mutation is fundamentally significant in GA because it
reintroduces genetic diversity back into the population which helps the algorithm
overcome local optima.178-179
Similar to biological processes, the reproduction comprises a selection of
chromosomes for the following generation. The fitness of individuals in a population
determines their probability of surviving through generations. The selection process
depends on how fitness functions are applied. Popular selection procedures include
proportional selection, and ranking.179
The GA algorithm used for the FIRMS model optimization was built by Frontline
Solvers utilizing Evolution Programs (EP) referenced in Michalewicz.178 It uses a
floating-point representation. The mutation methods are implemented as uniform, nonuniform (time-dependent), and bounds. The crossover methods include quadratic
interpolation following controlled random search algorithm (CRS6)181-182 and total and
partial arithmetic crossover (convex combination). However, in general, all GAs/EAs
methods follow the process described by:179
Step 1
Set t = 1, Produce N solutions randomly to form the first population, P1 and
evaluate the fitness of solutions in P1.
Step 2
Crossover: Produce an offspring population S1 through the following process:
2.1. Select two solutions x and y from population P1 based on fitness values.
2.2. Generate offspring and add to S1 using crossover operator.
Step 3
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Mutation: Mutate individual solution 𝒙 ∈ 𝑺𝟏 using a predefined mutation
rate.
Step 4
Fitness assignment: Assess and assign a fitness value to individual
solutions of 𝒙 ∈ 𝑺𝟏 based on its objective function value and infeasibility.
Step 5
Selection: Choose N solutions from S1 based on their fitness and
replicated them to 𝑷𝒕+𝟏.
Step 6
If the termination criteria is met, the process is stopped and the search
returns to the existing population otherwise 𝒕 = 𝒕 + 𝟏 and Step 2 is repeated.
3.2.11.2 Tabu search and Scatter search algorithms
There are other meta-heuristic optimization methods other than GAs/EAs that
have been shown as very effective in finding solutions for complex physical problems.
For example, they are effective for systems with nonlinear objective functions or
constraints with the possibility of a large number of discrete variables or nonsmooth,
discontinuity and presence of uncertainty in important data. Thus, to solve such complex
systems, researchers have trusted other metaheuristic methods, such as Tabu Search (TS)
and Scatters Search algorithms (SS).180, 183-184
3.2.11.2.1 Tabu search algorithms
Tabu search was developed as a computational algorithm for solving
combinatorial optimization problems with a wide range of applications, such as graph
theory, matroid settings, and general pure mixed integer programming problems. It can
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adapt and apply other existing methods (e.g., linear programming algorithms and
specialized heuristics) which allows it to overcome the limitations of local optimality.185
It was originally developed for combinatorial procedures applied in nonlinear problems186
and also different groups of problems that include scheduling and computer channel
balancing, cluster analysis, and space planning.187-190
Caballero et al.191 developed a novel TS for combinatorial optimization problems
with two approaches: 1) a local Tabu Search Algorithm that generated a list of locally
Pareto-equivalent solutions (non-dominant solutions with respect to the neighboring
solutions); 2) a procedure that strengthened solutions with a path-relinking strategy.191
Path relinking strategies were developed for use in TS and SS algorithms, Greedy
Randomized Adaptive procedures and discrete optimization field.180, 192-194 The strategy
follows the underlying principle that the direction of the path in a design space can be
better used to guide the search in that direction than a random one, with the hope of
finding good points. The direction (or path) can be determined by use of initial point and
a reference point. The reference is the best-known solution in the search space. For
example, given two points x and y (reference point) of a vector, the search space between
the two points is a linear combination of the vector variables in the space, and as such the
retained information about the reference point can lead to good solutions points.180, 192
Jaeggi et al.180, 195 developed the first multi-objective TS variant that is widely used today
for unconstrained functions and constrained optimization problem.
3.2.11.2.2 Algorithm
The TS is sequential and iterative, in which the search starts at a chosen point and
the algorithm picks a new point in the search space that becomes the next current point.
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The recently selected points are stored in the short-term memory (STM) and the search is
not allowed to return to the values. Optimal points are stored in medium term memory
(MTM) and are used for strengthening and directing the search on areas of the search
space with known good objective function values. The long-term memory (LTM) keeps
the record of regions of the search space explored and is used to strengthen and focus the
search in regions less explored. This is done by dividing each design variable into n
regions and keeping the count of evaluated solutions in that region. After a successful
addition to MTM, the process is reset using a counter until the counter reaches the userspecified value, and then the solution to the problem is produced.180
Mathematically, TS optimization can be applied in minimization via the
following steps.
Using Equation 10, one trial solution is selected in the space 𝒙 ∈ 𝛀. A subset 𝛀(𝐬) of 𝛀
is also created in the form: 𝛀(𝒔) → 𝛀. The space associated with 𝒙 ∈ 𝛀 is then defined
in the subset 𝑺(𝒙) that consists of the moves 𝒔  𝑺 that are applied for the x values.
Those elements in s are obtained by a non-Markovian function that uses information
stored from search process extended to t iterations in the past, where t can be a constant
or variable depending on the optimization problem. The values in s are well guided by a
set of tabu conditions, such as linear inequalities or logical relationships which are
expressed indirectly in the form of a trial solution x; for example, 𝒔(𝒙) = {𝒔  𝑺: 𝒔(𝒙)}
that may or may not defy the set tabu conditions. A simple tabu search process is
described in the simple example below for the function in Equation 10.185
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Step 1
Select an initial 𝒙  𝛀 and let 𝒙∗ : = 𝒙. Set the iteration counter 𝒕 = 𝟎 and begin
with S empty.
Step 2
If S(x) – s is empty, go to Step 4.
Otherwise, set 𝒌: = 𝒌 + 𝟏 and select 𝒔𝒌 ∈ 𝑺(𝒙) − 𝒔 such that 𝒔𝒌 (𝒙) =
OPTIMUM(s(x)):
𝒔  𝑺(𝒙) – 𝒔.
Step 3
Let 𝒙: = 𝒔𝒌 (𝒙). If 𝒇(𝒙) < 𝒇(𝒙 ∗), where x* denotes the best solution currently
found, let x*: = x.
Step 4
If a selected number of iterations has elapsed either in total or since x* was last
upgraded, or if 𝑺(𝒙) – 𝒔 =  (where  is an arbitrary value) upon reaching this
step directly from Step 2, stop.
Otherwise, update s (as subsequently identified) and return to step 2.185

In the above Tabu optimization: 1) s provides the constraints values, therefore the
solution found depends on values of s and the update process in Step 4; 2) there is no
reference to the condition of local optimum with the exception of areas where the local
optimum implicitly provides a better solution from previous values, and 3) the best move
is chosen at every step using the criteria in step 2 above.185
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Tabu search demonstrates its superiority over other classical optimization
methods through solving a problem by use of best available values that do not lead to
inferior solutions. Also, local optimum values do not provide an obstacle, therefore
enhancing the speed at which the local minimum might be considered and abandoned if
necessary. 185 The tabu search algorithm is recommended in many circumstances where
other traditional solvers cannot optimize complex nonlinear functions and find the best
global minimum solution.
3.2.11.2.3 Scatter Search Algorithms
Glover194 developed the scatter search method for finding starting solutions and
trial solutions of a function. It uses initialized values that are purposely generated to
account for the behavior of the function in numerous parts of the solution search space. It
works by orienting its explored values relative to a set of reference points. The reference
points might consist of good solutions found by prior problem-solving or evaluation of
functions.186 The scatter search performs the evaluation of a function through the
following procedure:
1. A starting set of solution vectors are generated by heuristic processes intended for
the evaluation of the problem under analysis. Some best vectors of the selected
subset are established as reference solutions.
2.

New points are created consisting of linear combinations of subset of the existing
reference solutions. These linear combinations are chosen to produce points both
in and outside the convex regions covered by the reference solutions. They are
also modified by a general rounding method to produce integer values for integer
constrained vector components.
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3. The best solutions generated in Step 2 are extracted as a group and then used as
initial points for a new application of the heuristic processes in Step 1. The
process is repeated until the required iteration limit is reached. An example of the
method is shown in the Figure 3.19 below.186

In Figure 15, the points labeled 1 through 16 are the designated central points for
a given subregion of the simplex A, B and C. Point B is the main central point of A, B,
and C. The points A, B C are not always used as the original points of reference. Any
coordinate point such as 16, 11 and 13 could be established as reference points. For
scatter search the choice relies on the distribution of the original points that are relative to
each other and also their feasibility. In order to ensure the desirable limits for larger
dimensions, the points produced as shown in the diagram are examined in a sequence
ascending order, or an alternative sequence that depends on the gradient of the objective
function contour. The generation of points continue until a desired point is reached as
shown in Figure 3.19, and sometimes less points might be considered.186
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Figure 3.19. Generated vectors of scatter search process.
SS has three important features namely: 1) the linear combinations are built with
the objective of producing weighted centers of selected subregions, hence allowing for
nonconvex combinations that focus the centers into regions outside the original reference
solutions. The dispersion pattern produced by such centers and their external focus are
applicable for mixed integer optimization; 2) the process for selecting specific subsets of
a solution are built to make use of clustering, hence allowing different types of important
variation by producing new solutions within and across the clusters; 3) they support
heuristics that are able to begin from infeasible solutions, therefore removing any
restriction that selected solutions for re-applying the heuristic method must be possible.186
The SS and TA algorithm provided by the Frontline Solvers were built as solver
engines using the work of Ugray et al.196 GAs/ EAs, TA and SS algorithms obtained
from the Frontline Solvers were found suitable for analysis of IRs using FIRMS methods.
They were integrated into the FIRMS graphical user interface (GUI) software.
3.3 FIRMS Software
3.3.1 Introduction
The software is a major component of the FIRMS method and the main
computational tool used in the analysis of tandem MS data for FIRMS compounds. The
models created by FIRMS using the information from molecular fragmentation data of
compounds obtained via tandem mass spectrometry were impossible to solve analytically
and too complex to solve numerically without the help of advanced computation. The
complexity of the models and functions increased from simple molecules to complex
molecules with long chain branches, rings, functional groups and in some cases,
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rearrangement, bond formation and occurrence of protonation, deprotonation . Moreover,
determining the combination of atoms that produce a particular fragment of molecular ion
was extremely difficult for molecules with more than two atoms and elements. The
complexity of FIRMS models and functions were further amplified by the molecules that
fragment from a molecular ion mass M+2. Finding solutions for the FIRMS models and
functions were therefore impossible by hand and necessitated the use of FIRMS software
that is integrated with simulation optimization solver.
3.3.2 C# programming language
There are dozens of computer programming languages in existence. For example,
Alice, APL, COBOL, Pascal, Eiffel, FORTRAN, Haskell, Mercury, ML, Mondrain,
Oberon, Perl, Python, RPG, Scheme, Smalltalk, C, C++, Visual F# and C# among many.
We chose to build the FIRMS software in C#197-198 language for the reasons discussed
below.
C# was originally created from scratch for .NET, which is a platform in which
computer programs run and was designed as a new programming paradigm. It is not an
operating system, like Windows platforms, but it is a layer between the operating system
and other applications. Thus, it offers a platform for developing and running computer
code that is easy and efficient to use with a set of development tools. Some of the
standard features of .NET are:197
•

Multilanguage independence: It supports the development of computer
applications using a number of programming languages i.e., Visual Basic, C# and
C++ and also third-party languages that compile to the established Microsoft
Intermediate Language (IL). This can allow parts of an applications to be
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developed in different languages like Visual Basic and C# then translated to a
common IL.
•

New Framework base classes: It has a class library, which provides an expansive
collection of more than 2500 reusable classes available to the .NET languages.

•

Dynamic Web pages and Web services: .NET can deploy applications over
intranets or internet using ASP.NET, ADO.NET and XML which allow access to
relational databases, and import and export data through internet web.

•

Scalable component development: .NET supports object-oriented programming
and development that is faster and easier in terms of performance. It allows the
creation of components of codes as individual entities, and can be kept
independently, reused or combined with other applications. These components
can be created in different languages.

For these reasons, the .NET platform was used for FIRMS. Thus, it was very
convenient to use C# programming language since it was created and designed for the
.NET platform. The large number of classes included as part of .NET could, therefore, be
used and new classes easily designed in C# language. As a result, it would reduce the
algorithms and programming codes needed for FIRMS software. Moreover, C# coupled
together with .NET Framework classes, offered an opportunity to incorporate and use
emerging Web standards, for example, Hypertext Markup Language (HTML), Extensible
Markup Language (XML), and Simple Object Access Protocol (SOAP) which makes it
easy to download updates for FIRMS software via internet. Additionally, the Visual
Studio IDE and the .NET Framework provided a simple platform to create graphical user
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interfaces (GUI) which is an essential component of FIRMS software. C# also offers
excellent data handling speed to which C and C++ programmers are used to. C# also
enables programmers to build packages available over the internet using many standard
features available only in Java, Common Gate-way Interface (CGI), or PERL.197 Thus,
users who would like to couple their applications with FIRMS would find it easy to do so
without having to convert their apps algorithm into C#.
3.3.3 FIRMS software components
The FIRMS software has the following major components: GUI, structural
modeling algorithm, combinatorial data structure algorithm, IRs calculation algorithm,
import data and compound structures algorithms, export data algorithms, and simulation
optimization solver algorithms.
3.3.3.1 Structural modeling algorithm
The molecular structures of organic compounds analyzed by FIRMS are imported
from PubChem. The process involves extracting molecular structures in canonical
SMILES format. SMILES is chemical notation language designed for converting an
arbitrarily selected description of a chemical structure to one distinctive notation. The
notation is unique in order to preserve the identifier of the specific structure for database
and other computer applications.199
SMILES chemical notations involve a method known as CANGEN which
combines two separate algorithms, CANON, and GENES. In the first step, CANON
labels a molecular structure with canonical labels and treats it as a graph with nodes
(atoms) and edges (bonds). Each atom acquires a unique numerical label based on its
topology. In the second step, GENES generates the distinctive SMILES notation as a tree
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diagram of the molecular graph. The GENES choose the starting atoms, and builds and
makes decisions in reference to the canonical labels as required. These two processes
designate a unique SMILES notation for every chemical structure irrespective of the
existence of many possible equivalent descriptions of the structures.199 An example of
SMILES is shown below using the structure of vardenafil.
SMILES

CANGEN

CCCC1=NC(=C2N1NC(=NC2=O)
C3=C(C=CC(=C3) S(=O) (=O)
N4CCN(CC4) CC) OCC) C

Figure 3.20. Conversion of vardenafil into SMILES.

The SMILES format of the molecule is then converted to a 2D Chemical Markup
Language (CML) format using the Open Babel utility. CML was developed by MurrayRust et al.,200 as an operational system for managing complex chemical content in
interoperating XML-based markup languages. It incorporates the CML 1.0 and a
mechanism that displays CML molecules within a standard web browser. It has
significant advantages of data recovery capabilities and flexibility over other existing
computer HTML/plugin solutions.200-202
Open Babel is an open-source chemical toolbox written in computer codes based
on languages of chemical data. It provides a platform for multiple chemical file formats
with additional utilities of 2D depiction, filtering, batch conversion, and substructure and
similarity searching. Researchers and developers use it as a programming library for
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handling chemical data in disciplines including drug design, organic chemistry, materials
science and computational chemistry.203
After the process that involves SMILES, CML and Open Babel, the formatted 2D
CML information obtained from Open Babel is saved in the FIRMS files directory and
can be imported into the FIRMS GUI as a new XML file. Once a molecular ions structure
is imported in FIRMS GUI, the user can select different atoms within the structure to
associate with fragments observed in the mass spectrum of a molecule. The user also has
the ability to manipulate the structure to account for rearrangements, multiple bond
formation, and protonation or deprotonation within a molecular ion. When users are
satisfied with the structures created, they continue to the next step of producing a model
that represents the structure.
3.3.3.2 Combinatorial data structure algorithm
The structure selected by the user, which is associated with a fragment in the mass
spectrum is linked together with the stack data structure algorithm previously discussed
(Section 3.2.9) to create all accepted combinations of atoms that produce the fragment
mass observed in the mass spectra. Once these models are created, they are linked to
tandem mass spec data for further analysis and calculation.
3.3.3.3 Import data and structure algorithm
The FIRMS software allows the user to import data extracted from MS data
analysis software and link the fragments with the structural models created in the GUI.
Specifically, the structural fragments drawn by the user are assigned to specific m/z
values from the mass spectral data.
3.3.3.4 IRs calculations, export, and numerical solver algorithm
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Once the computer models are created and mass spectra are imported into the
software, the user sets constraints and tolerances and directs the software to initiate the
numerical solver. At the end of optimization, the FIRMS software displays the results in
the form of isotope frequencies, their standard deviations, and calculated  values. The
information obtained by the user can be then be used to characterize the compound in
order to draw a conclusion.
3.4 Significance of FIRMS
While other IR analysis techniques have been excellent at accurately determining
IRs, FIRMS was developed in order to compensate for other limitations of these
techniques. The first important role that FIRMS would play as a new method of IRs
analysis is the ability to investigate the structure of a molecule under analysis. This is a
current problem with IRMS and CRDS, in which combustion is necessary to produce a
gas that is then ionized and measured against standard gases. The standard gases include
N2, CO2, SO2, and H2O. Due to loss of structure, it is extremely difficult to identify
compounds in situations where unknown compounds are analyzed. Also, in a mixture of
several molecules, converting each component into a gas generates problems, because it
is impossible to associate simple gas molecules produced with a specific compound in the
mixture. With FIRMS, it is easy to evaluate the IRs of individual molecules of a mixture.
This is because mass spectral techniques have excellent resolution and sensitivity that can
be used to identify a molecule. Furthermore, FIRMS relies on mass fragments of
precursor ions (product ions) to analyze IRs. Every molecule fragments differently in a
mass spectrometer, which makes identification easier in many cases. On the other hand,
FIRMS can also be directly coupled with chromatography methods that will separate
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components of mixtures. Moreover, co-eluting components would theoretically not
interfere with the IR analysis of each.
Secondly, FIRMS reduces the possibility of contamination. NRM, CRDS, and
IRMS are prone to contamination during sample preparation, and introduction. Standard
gases might also be contaminated. FIRMS eliminates this problem by targeting a
particular mass to charge, and uses both precursor and product ions.
Third, most IR analysis techniques produce aggregate isotope ratios of the atoms
present in a molecule. For example, by converting a molecule to CO2, both IRMS and
CRDS analyze the aggregated value  13C/12C as one number despite the fact that most
organic compounds have more than one carbon present. FIRMS has the ability to analyze
each atom or group of atoms separately to determine IRs at specific locations in a
molecule.
3.5. Conclusion
FIRMS, a nonlinear mathematical model was developed with the potential to
analyze the isotope ratio of organic compounds. The theorem was proved to be true and
can model a structure of any organic compound by utilizing FIRMS data structure
algorithms. Theoretically it has been shown that Evolutionary/Genetic, Tabu and Scatter
search algorithms are the relevant methods of minimizing the objective functions of
FIRMS based on full characterization and analysis of FIRMS functions. However,
Evolutionary (a non-gradient based) algorithm will be used in developing FIRMS and
will be compared to gradient based Generalized Reduced Gradient (GRG) methods for
validation. Additionally, computations and data structures proved to be valuable in
putting together the FIRMS graphical user interface in C# programming language.
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Chapter 4: Analysis of Evolutionary/Genetic Algorithms (EA/GA), Generalized
Reduced Gradient (GRG) & Multi-start GRG
4.1. Introduction
Problems with multiple objectives naturally arise in many disciplines. Calculating
solutions to these problems is difficult for scientists to this day. Although there are many
techniques that may solve these problems, the complexity of the mathematical analysis
involved has influenced the development of alternative approaches. Additionally, some
MOO problems are so complex that the use of standard multiobjective techniques does
not provide adequate results. Complexity can manifest as a large search space,
uncertainty, noise, and discontinuity of Pareto curves. The application of EA/GAs to find
solutions for MOO problems has been of interest to many researchers. Mainly because of
their population-based nature, EAs allow the production of several elements of the Pareto
optimal set in a single analysis. Thus, given the nature and complexity of FIRMS
functions, three alternative approaches to solving MOO problems were evaluated for their
performance in solving the FIRMS MOO problem. EA/GA, a non-gradient algorithm,
GRG (gradient based), and Multistart GRG (gradient based) algorithms were compared to
evaluate the most appropriate numerical optimization algorithm. As discussed in Chapter
3, FIRMS functions should require non-gradient based algorithm, and GRG was included
to test this hypothesis.
4.2 EA/GA versus GRG
Frontline Systems Inc. recommends Multistart GRG and Evolutionary algorithms
for optimization of non-convex and nonsmooth functions, such as FIRMS equations.
GRG (non-gradient) is ineffective at analyzing non-convex problems because the
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solutions found are local extrema rather than global extrema. However, Multistart GRG is
capable of evaluating many different locations and initial values within a domain and
examines the best solution. But both GRG and Multistart GRG require derivatives for
continuous functions. FIRMS equations of the form 𝑐(𝑥) = |𝑓(𝑥)𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 −
𝑓(𝑥)𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 are not differentiable where 𝑐(𝑥) = 𝑓(𝑥)𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 the solution point.
This is the reason why FIRMS IRs theory argues for non-gradient based optimization
methods, such as Tabu search, Scatter search and EA/GA. To test this hypothesis, a nongradient based algorithm was compared with the performance of gradient-based
algorithms. Thus, a study was initiated to compare the accuracies of GRG and Multistart
GRG, gradient-based methods, to the EA/GA non-gradient based method using several
organic compounds.
4.3 Evaluation of EA/GA and GRG algorithms using organic compounds
Several trials were conducted on EMPA, p-toluenesulfonic acid monohydrate and
5-sulfosalicylic acid dihydrate. The isotope abundance variables were held constant for
each compound (e.g., 12C, 13C, 1H, 2H, 16O, 17O and 31P for EMPA). Different settings of
constraints were used based on linear inequalities with varying settings for each type of
solver. For example, in the Evolutionary solver, the mutation rate was varied between
0.075 and 0.2 while GRG solver was alternated between the Multistart GRG and standard
GRG.
The data used to evaluate the two algorithms were calculated using Equations 5
and 6 with total abundances for the base mass (M) experimentally determined, and 
values calculated based on Equation 7-10, given an  calculated using Equations 2 and 3.
The solver minimized the objective value calculated from these data to give  values. 
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values calculated by GRG and EA were then compared to the real  calculated from the
known isotope abundances of elements. The average, standard deviation, minimum,
lower quartile, median, upper quartile, maximum, and range of the sum of absolute
differences from true  values (IRs), and of the sum of absolute differences between the 
values after optimization were analyzed.
Comparison of the results produced by GRG and Evolutionary algorithms showed
that the latter outperformed the former. As shown in Table 4.1, the average sum of
absolute difference between the real  values and those calculated by EA shows that EA
results were significantly lower, meaning EA results were more accurate than GRG.
Similar results were observed when evaluating standard deviations, minimum, maximum,
lower and upper quartile, and median. Moreover, the range of sum of absolute differences
of  observed were greater for GRG than EA, which means that GRG  values were
significantly far from the real solution.

Table 4.1. The difference of sum of absolute  values.

Compound
EMPA
p-Toluenesulfonic acid
monohydrate
5-sulfosalicylic acid dihydrate

Sum of absolute  differences
Algorithm
Average Standard
Deviation
EA
170.7
159.4
GRG
218.8
180.3
EA
356.0
87.5
GRG
394.3
159.1
EA
543.6
134.8
GRG
556.7
149.9

Minimum

Maximum

9.5
56.7
257.3
200.5
300.5
283.1

397.9
928.3
511.2
541.5
669.0
669.2
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Figure 4.1. A plot of sum of absolute difference of  values (y axis) and  values (x axis)
for EMPA. The average sum of absolute difference between the real  values and those
calculated by EA shows that EA results were significantly lower meaning EA results
were more accurate than GRG.

Figure 4.2. A plot of sum of absolute difference of  values (y axis) and  values (x axis)
for p-Toluene sulfonic acid monohydrate. The average sum of absolute difference
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between the real  values and those calculated by EA shows that EA results were
significantly lower meaning EA results were more accurate than GRG.

However, finding accurate solutions did not mean that EA minimized the
objective function better than GRG algorithms. On the contrary, as shown in Figures 4.1
and 4.2, for the same analysis GRG methods minimized the objective functions to the
lower values than EA algorithms. The small difference between calculated and
experiment  suggested that GRG algorithms are sometimes better in terms of
optimization performance.
Figure 4.3 shows the  differences of different trials, indicating that the EA and
GRG algorithms appear to have similar or parallel characteristics, with EA performing
better than GRG. For each adjacent pair of GRG data, the first is regular GRG and the
second is Multistart GRG. And for an adjacent pair of EA, the first is Evolutionary with
mutation rate 0.075, and the second is Evolutionary with mutation rate 0.2. This figure
shows that individual configuration and changing different parameters may improve or
give undesired results. For example, for trial 4, the mutation rate of 0.2 produced 
solutions with a larger error compared to mutation rate of 0.075.
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Figure 4.3. The  differences for 5-sulfosalicylic acid dihydrate against the trial numbers.
Each pair of data have different parameters being tested. It shows that individual
configuration and changing different parameters may improve or give undesired results.

4.4. Conclusion
Overall, the solutions found using the Evolutionary algorithm were more accurate
compared to solutions produced by GRG algorithms. However, some of the GRG minima
for  were smaller than the minima calculated by EA/GA. However, Figure 4.3 also
shows that EA/GA solutions were more accurate compared to GRG. The reason for this
observation is because EA/GA tends to find solutions corresponding to more gradual
declines that revolve around the true solution. On the other hand, GRG appears to find
steep and narrow troughs that may exist far from the true solution. Thus, EA/GA was
selected as the most appropriate algorithm for optimization of FIRMS objective functions
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Chapter 5: Materials and Method
5.1 Reagents and Standards
Ammonium hydroxide, methanol, ethanol, isopropyl alcohol, acetonitrile and
acetone (HPLC-grade or higher), formic acid, o-phosphoric acid hydrochloric acid, and
acetylsalicylic acid were purchased from Thermo Fisher Scientific (Ward Hill, MA,
USA). Ethyl methylphosphonic acid (EMPA) was acquired from Cerilliant (Round Rock,
TX, USA). 3-chloro-2-nitrobenzoic acid, 2,3-dicyanohydroquinone, L-histidine
monochloride, L-tyrosine, o-tert-butyl-L-tyrosine, eugenol, caffeine, 3,4-dibromo
benzaldehyde, 3-phenylpropionic acid, 4-nitrobenzaldehyde, p-toluene sulfonic acid
monohydrate, tert-butyl chloride, and caffeine were acquired from Sigma-Aldrich (St.
Louis, MO, USA). Diisopropyl methylphosphonate (DIMPA) and p-toluene sulfonyl
chloride were purchased from Acros Organics (Morris Plains, NJ, USA). 5-chloro-2methylbenzoic acid was purchased from both Sigma-Aldrich (St. Louis, MO, USA) and
Alfa Caesar (Tewksbury, MA, USA).
5.2 Sample preparation
Compounds were dissolved in various solvents, as shown in Table 5, to produce 5
mM stock solutions. The solutions were further diluted to create standards with
concentrations between 60 and 100 M for analysis using DLSI-MS-MS, and LC-MS-MS.
In general, FIRMS analysis included four major steps: 1) the analysis of a
compound using MS to identify fragments and transitions of interests; 2) the collection of
MS-MS data using DLSI and/or chromatography; 3) converting the MS-MS data to the
FIRMS format, including selection of fragments, boundaries, and constraints, and 4)
calculating 13C using FIRMS software.
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Table 5.1. Analytes and solvents used to create the desired concentration standard.
#
Compound
1 Acetylsalicylic Acid
2 Caffeine
3 5-chloro-2-methylbenzoic acid1
4 5-chloro-2-methylbenzoic acid2
5 3,4-dibromo benzaldehyde
6 2,3-dicyano hydroquinone
7 Diisopropyl methyl phosphonic acid3
8 Diisopropyl methyl phosphonic acid4
9 Ethyl methyl phosphonic acid
10 Eugenol
11 L-Histidine
12 4-nitrobenzaldehyde
13 3-Phenylpropionic acid
14 o-tert-butyl-L-Tyrosine
15 L-tyrosine
16 p-Toluene sulfonyl chloride
17 p-toluene sulfonic acid
1
China, 2India, 3France, 4Great Britain

Solvent
Ethanol
Acetone
Methanol
Methanol
Methanol
Methanol
Water
Water
Water
Methanol
Water
Methanol
Methanol
Aqueous Formic Acid (1 mM)
Aqueous Formic Acid (1 mM)
Methanol
Methanol

Conc
(M)
100
100
100
100
100
100
60
60
60
60
100
100
70
70
100
100
80

5.3 Direct liquid sample introduction analysis (DLSI)
The standards prepared according to Table 5.2 were analyzed using an AB Sciex
Q-trap 5500 MS-MS (Applied Biosystems, Foster City, CA, USA) DLSI to acquire
precursor and product ions scans. The standards were introduced using a 1 mL Luer Lock
Gastight Syringe (Hamilton Robotics, Reno, NV, USA). The declustering potential (DP)
and collision energy (CE) were optimized for product ions (fragments) of interest. A
multiple reaction monitoring (MRM) method was developed using the optimized
parameters and used to detect MRM product ions in either negative or positive polarity,
depending on the compound being analyzed. For example, MRM transitions for L-histidine
monochloride are listed in Table 5.2. MRMs were monitored consecutively for 100 ms
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each for a total of 10 minutes at a flow rate of 10 L/min for five different days. At the end
of each sample analysis, product ion abundances of each transition for the compounds were
extracted as text files for analysis using the FIRMS software.
Table 5.2. MRM transitions for L-histidine monochloride including declustering potential
(DP) and collision energy (CE) measured in volts (V).

Precursor Ion(Da)
156.0
156.0
156.0
156.0
156.0
157.0
157.0
157.0
157.0
157.0
157.0
157.0
157.0
157.0
157.0

Product ion (Da)
56.0
66.1
83.0
93.1
110.0
56.1
57.0
66.1
67.0
83.1
84.0
93.0
94.1
110.1
111.1

DP(volts)
79.83
91.74
46.61
75.56
18.49
26.46
80.62
19.34
59.12
40.31
58.27
17.55
20.34
66.81
60.12

CE(volts)
44.91
58.37
34.49
30.41
18.15
54.74
48.90
57.36
53.56
36.27
36.79
37.06
31.02
17.81
17.51

5.4 LC-MS-MS analysis
Liquid chromatography-tandem mass spectrometry (HPLC-MS-MS) experiments
were conducted for five different (sometime consecutive) days to evaluate the applicability
of FIRMS when performing separation via LC. A Shimadzu HPLC (LC-20AD, Shimadzu
Corp., Kyoto, Japan) was coupled to the AB Sciex Q-Trap 5500 MS. MRM parameters, as
described in Section 5.3, were used. Caffeine, acetylsalicylic acid and, DIMPA were
analyzed via LC-MS-MS. MRM transitions are listed in Tables 5.3 - 5.6.
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Table 5.3. LCMSMS MRM transitions for caffeine including declustering potential (DP)
and collision energy (CE) measured in volts (V).
Precursor Ion
194.6
194.6
194.6
194.6
195.6
195.6
195.6
195.6
195.6
195.6
195.6
195.6

Product Ion
69.1
83.1
110.1
138.1
69.1
70.1
83.0
84.1
110.1
111.1
138.1
139.1

DP(V)
178.97
208.00
168.12
49.910
166.05
88.870
114.51
111.51
70.930
122.97
27.190
100.56

CE(V)
36.29
37.50
33.58
33.30
26.59
44.46
42.85
57.76
32.21
43.45
26.33
26.69

Table 5.4. LCMSMS MRM transitions for acetylsalicylic acid including declustering
potential (DP) and collision energy (CE) measured in volts (V).
Precursor Ion
179.0
179.0
180.0
180.0
180.0
180.0

Product Ion
59.0
93.0
59.0
60.0
93.0
94.0

DP(V)
-57.72
-40.49
-52.77
-69.90
-20.25
-28.66

CE(V)
-14.22
-31.42
-39.56
-30.03
-32.03
-31.44

The LC separation was carried out using a C8 (ZORBAX Eclipse XDB-C8, 5 µM
4.6 x 150 mm) reversed-phase column (Agilent, USA) with analytical guard column C8
(ZORBAX 4.6 x12.5 mm 5-Micron). The analytes were eluted isocratically at a flow rate
of 0.25 mL/min with 25.0%, 25.0%, 50.0% and 0.1% (v/v) isopropyl alcohol, acetonitrile,
water and formic acid204 respectively. The DIMPA LC method generally followed the
method of Appel et al.205 using transitions in Table 5.5 shown below. The isotope
abundance data were extracted by analyzing chromatographic peaks between time intervals
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of peak elution above noise and summing the abundances within the time range. The
abundances were analyzed using FIRMS software in order to calculate isotope ratio values.
Table 5.5. LCMSMS MRM transitions for DIMPA originating from France including
declustering potential (DP) and collision energy (CE) measured in volts (V).

Precursor Ion
181.1
181.1
182.1
182.1
182.1
182.1

Product Ion
79.0
97.0
79.0
80.0
97.0
98.0

DP(V)
36.65
67.71
43.51
77.66
35.70
43.27

CE(V)
46.18
25.35
44.40
44.03
20.60
18.48

Table 5.6. LCMSMS MRM transition for DIMPA originating from Great Britain including
declustering potential (DP) and collision energy (CE) measured in volts (V).

Precursor Ion
181.1
181.1
182.1
182.1
182.1
182.1

Product Ion
79.0
97.0
79.7
80.0
96.9
97.9

DP(V)
30.46
111.24
112.78
86.48
4.600
4.840

CE(V)
47.00
18.73
50.05
56.43
12.62
11.55

5.5 IRMS analysis
Pure compounds of interest (Table 5.1) were analyzed via IRMS. Solid compounds
were ground through a 2-mm screen with a centrifugal grinding mill (Retsch ZM-1,
Brinkmann Instrument Co., Westbury, NY, USA). Samples (3 mg each) were analyzed for
total C and 13C isotope abundance (13C relative to total 12C + 13C) on a 20-20 Europa isotope
ratio mass spectrometer (Europa Scientific Ltd., Crewe, Cheshire, UK). Compounds which
are liquid at room temperature were mixed with 3 mg Chromosorb W and analyzed for
total C and

13

C isotope abundance. A standard sample was evaluated after every eight
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samples. The standard used for solid samples was bleached all-purpose wheat flower
purchased from a local market source with standard values previously verified through
multiple testing labs. The standard used for liquid samples, Fish tissue, was obtained from
the Natural Resource Management department at South Dakota State University, and was
previously verified through multiple testing labs.
5.6 FIRMS software
Genetic Algorithm (GA), Tabu Search (TS) and Scatter Search (SS) algorithms
were acquired from Frontline Systems Inc. (Incline Village, NV USA) and used to
minimize the objective function (i.e., differences between the calculated and
experimental  values (Equation 21) produced from the tandem MS, LC-MS-MS and
GC-MS-MS data). The minimization was performed twenty times on the data collected
for each day. For each data set, the 13C was calculated by averaging twenty calculated
13C values produced by FIRMS algorithms. A 13C value was only included on the
average when the EA algorithm produced a “converged” solution and the objective
function value was lower than the original objective value function. The average 13C
value was calculated from isotope abundance of all five data sets. The isotope
abundances for the multi-objective optimization (MOO) problems were reported as ∂13C
measured in ‰ (parts per mill).

93

94
Chapter 6: Results and Discussion
6.1 Mass Spectrometry
Mass Spectra and Molecular Ion Fragmentation for FIRMS
Multiple compounds (N = 17) were evaluated both by FIRMS and IRMS to
quantify the performance of FIRMS compared to the current “gold standard” technique
for measuring isotope ratios (i.e., IRMS). The relative abundances of tandem MS product
ions were analyzed using the FIRMS software. Selected MS spectra of these compounds,
including IMPA and p-Toluenesulfonic acid monohydrate and their identified fragments
are discussed below. They include precursor ion and product ion scans for molecular ions
of mass M and M+1.
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Figure 6.1. Simplified tandem mass spectral data for isopropyl methylphosphonic acid
(IMPA). (A) Precursor ion scan (Q1- scan) of IMPA showing the molecular ion. (B)
Product ion scan of m/z = 137. (C) Product ion scan of m/z = 138.1. The differences
between the product ion scan of the base mass (m/z = 137) and the heavier stable isotope
(m/z = 138.1) can be attributed to the isotope ratios of the atoms involved.
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Figure 6.2. Simplified tandem mass spectral data for p-Toluenesulfonic acid
monohydrate. (A) Precursor ion scan (Q1-scan) of p-Toluenesulfonic acid monohydrate.
(B) Product ion scan of m/z = 171.1. (C) Product ion scan of m/z = 172.1. The
differences between the product ion scan of the base mass (m/z = 171.1) and the heavier
stable isotope (m/z = 172.1) can be attributed to the isotope ratios of the atoms involved.

The fragmentation of precursor ions during FIRMS analysis was achieved through
collision-induced dissociation (CID) in the MS after initial ionization of precursor ions.
These ions were either negatively charged or positively charged. For example, IMPA,
EMPA and acetaminophen have molecular weights of 138.103 g/mol, 124.076 g/mol and
151.165 g/mol, respectively. Their molecular formulas are C4H11O3P, C3H9O3P, and
C8H9NO2, respectively. However, deprotonation occurs during ionization or before
ionization, thus forming precursor ions of 137.0, 123.0 and 150.2 m/z with formula of
C4H10O3P- and C3H8O3P-, and C8H8NO2-, respectively. DIMPA has a molecular weight of
180.184g/mol, and molecular formula of and C7H17O3P. It forms a precursor ion of 181.1
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m/z which means that DIMPA undergoes protonation to form a molecular ion
C7H18O3P+. Other compounds, such as L-histidine chloride, and p-Toluenesulfonic acid
monohydrate lost larger fragments during precursor ion filtration, losing chlorine and
water, respectively.
Some of the products ions, such as caffeine ions, were produced by rearrangement
of molecular ions. The rearrangements of compounds generally included conversion of
single bonds to double or triple bonds, conversion of straight chain carbons to a ring or
opening of a ring to form straight chain carbons.
Given that the abundances correlate with isotope ratios and isotope frequencies as
mentioned in Chapter 3, the MS data were used to calculate the unknown isotope values
shown in Section 6.4. The FIRMS software was used to calculate the isotope abundance
values 13C of compounds measured in parts per mil based on complex mathematical
formulation and numerical minimization. As shown in Section 6.3, FIRMS data were
accurate with excellent precision and accuracy (measured as an absolute error), < 1‰ and
< 1.6‰ compared to IRMS values, respectively. This precision is within the generally
accepted isotope abundance precision range of  1‰ for 13C.117 The R2 (coefficient of
determination) shown by a bivariate plot of IRMS versus FIRMS technique of the
compounds was 0.992 with a slope of 1, as shown in Figure 6.6. FIRMS showed both
good precision and accuracy versus the “gold standard” of IRMS, validating it as an
accurate method for measurement of isotope ratios.
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6.2 FIRMS LCMSMS
Three compounds, acetylsalicylic acid, caffeine and DIMPA were analyzed using
liquid chromatography. The data were collected over a period of 5 days in order to
evaluate day-to-day variability of the isotope ratios calculated by FIRMS. Figures 6.3,
6.4, and 6.5 show single day triplicate liquid chromatograms of DIMPA, acetylsalicylic
acid and caffeine respectively.
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Figure 6.3. A) Liquid chromatograms of DIMPA originally from France for 181 m/z
transitions. B) DIMPA chromatograms for 182 m/z transitions.
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Figure 6.5. A) Liquid chromatograms of caffeine for 195 m/z transitions. B) Caffeine
chromatograms for 180 m/z transitions.

The use of chromatography to separate complex samples prior to MS-MS analysis
open up FIRMS to a much wider application space. Although FIRMS-LCMSMS is
theoretically possible, the typical LC peak only allows data collected for a short period of
time, compared to 10 minutes of DLSI method. Therefore, the error associated with
LCMSMS may be larger than FIRMS DLSI-MSMS. For example, LC method for
caffeine involved analysis of peak abundance between 6.5 and 7.5 minutes. This was
compared to caffeine abundances data acquired via DLSI method for 10 minutes.
The DIMPA, acetylsalicylic acid and caffeine chromatograms used for FIRMS
analysis were non-smooth and lack sharpness required for chromatographic research
work. There was also presence of tailing observed. In general, this would be a concern,
but for FIRMS we were more interested in the mean abundances of the peaks than the
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quality of chromatograms. Thus, it was concluded that acetylsalicylic acid, caffeine and
DIMPA chromatograms provided the required data despite the peak shapes. The isotope
abundance values calculated using LC data were significantly accurate with good
precision of  1‰, and accuracy of < 1‰ compared to IRMS values.
LC method results show that the overall accuracy was excellent compared to
DLSI method of the same compounds. Although we hypothesized that we will observe
lower accuracy compared to DLSI method the opposite was established with LC method.
We had expected lower accuracy because of the fact that collecting data over 10 minutes
gradually minimizes error by normalizing peak abundance values. Peaks analyzed over a
short amount of time are likely to have larger errors. Thus, the LC method results would
show slightly inaccurate data compared to IRMS and DLSI-FIRMS method. Because the
precision and accuracy for 13C were  1‰, and because there was a small difference
between LCMSMS-FIRMS results and IRMS, FIRMS can be coupled with LC methods
to analyze a single compound or a mixture of compounds.
6.3 Isotope ratio calculations by FIRMS
All data collected using various sample methods, including DLSI, HPLC and GC,
were analyzed using FIRMS. As shown in Table 6.1, the precision and accuracy of 13C
measured by FIRMS method were < 1‰ and < 1.6‰ hence meeting the standard
requirements. These precisions significantly matched IRMS values or showed better
precisions in some circumstances.
FIRMS isotope abundance values were relatively accurate as compared to IRMS
measurements without any standardization involved. A bivariate plot (Figure 6.6) of
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FIRMS versus IRMS for a total of 17 compounds produces a coefficient of determination
(R2) of 0.992 and a slope of 1. The R2 and slope of 1 demonstrated the validity of FIRMS.
Table 6.1. Results of FIRMS 13C, standard deviations, accuracy (absolute error in ‰)
and RSD

#

Compound

1 Acetylsalicylic acid
2 Caffeine
3 5-chloro-2-methylbenzoic acid1
4 5-chloro-2-methylbenzoic acid2
5 3,4-dibromo benzaldehyde
6 2,3-dicyano hydroquinone
7 Diisopropyl methyl phosphonic acid3
8 Diisopropyl methyl phosphonic acid4
9 Ethyl methyl phosphonic acid
10 Eugenol
11 L-Histidine
12 4-nitro benzaldehyde
13 3-phenylpropionic acid
14 O-tert-butyl-L-tyrosine
15 L-tyrosine
16 p-toluene sulfonic acid
17 p-toluene sulfonyl chloride
1
China,2India,3France,4Great Britain

IRMS
13C
(‰)
-30.13
-30.11
-29.01
-29.14
-27.20
-36.11
-31.80
-31.06
-33.57
-31.82
-7.483
-30.21
-27.27
-21.46
-26.02
-26.45
-27.76

SIRMS

(‰)
0.10
1.58
0.35
0.67
0.23
0.07
0.33
0.07
0.10
0.56
0.10
0.19
0.05
0.00
0.05
0.02
0.00

FIRMS
13C
(‰)
-30.29
-30.28
-28.74
-29.03
-27.83
-36.26
-31.40
-31.35
-32.80
-30.86
-7.240
-30.72
-27.95
-20.87
-26.62
-27.50
-27.76

SFIRMS
(‰)

Accuracy
(‰)

0.27
0.50
0.22
0.41
0.65
0.73
0.68
0.59
0.27
0.34
0.65
0.57
0.44
0.40
0.46
0.69
0.42

-0.16
-0.17
+0.27
+0.11
-0.63
-0.15
+0.41
-0.30
+0.77
+0.96
+0.24
-0.51
-0.68
+0.59
-0.60
-1.05
0.00

Table 6.2. Results of FIRMS-LCMSMS 13C, standard deviations, accuracy (absolute
error in ‰) and RSD
#

Compound

1 Acetylsalicylic Acid
2 Caffeine
7 Diisopropyl methyl phosphonic acid1
8 Diisopropyl methyl phosphonic acid2
1
France, 2Great Britain

LC-FIRMS
13C (‰)
-30.06
-29.76
-31.37
-30.30

Accuracy
(‰)
-0.07
+0.35
+0.43
-0.76

SFIRMS
(‰)
0.64
0.66
0.85
0.15

104

105
6.4 Isotope Ratios Mass Spectrometry (IRMS) analysis versus FIRMS
In order to validate FIRMS method for 13C calculations, several compounds
were analyzed using IRMS. The average  values, standard deviations and %RSD of
those compounds are represented in the Table 5.5 below. These results showed good
precisions of  1‰ with % RSD  6%.
Table 6.3. Results of IRMS ∂13C, standard deviations, and RSD
# Compound
1 Acetylsalicylic acid
2 Caffeine
3 5-chloro-2-methylbenzoic acid1
4 5-chloro-2-methylbenzoic acid2
5 3,4-dibromo benzaldehyde
6 2,3-dicyano hydroquinone
7 Diisopropyl methyl phosphonic acid3
8 Diisopropyl methyl phosphonic acid4
9 Ethyl methyl phosphonic acid
10 Eugenol
11 L-Histidine
12 4-nitro benzaldehyde
13 3-phenylpropionic acid
14 O-tert-butyl-L-tyrosine
15 L-tyrosine
16 p-toluene sulfonic acid
17 p-toluene sulfonyl chloride
1
China,2India,3France,4Great Britain

IRMS 13C (‰)
-30.13
-30.11
-29.01
-29.14
-27.20
-36.11
-31.80
-31.06
-33.57
-31.82
-7.483
-30.21
-27.27
-21.46
-26.02
-26.45
-27.76

SIRMS (‰)
0.10
1.58
0.35
0.67
0.23
0.07
0.33
0.07
0.10
0.56
0.10
0.19
0.05
0.00
0.05
0.02
0.00

FIRMS showed good accuracy compared to IRMS analysis of the same
compounds. Figure 6.6 shows a linear relationship between FIRMS and IRMS analysis of
the same compounds. The high R2 value of 0.992 shows that 99% of the variance is
accounted for data falling within the regression model indicating a good fit between two
independent methods. Thus, the bivariate plot of IRMS versus FIRMS validates the
FIRMS as an accurate new method for isotope ratio analysis.
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Figure 6.6. The bivariate plot of IRMS versus FIRMS showing the validation of the
FIRMS as an accurate new method for isotope ratio analysis.
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Chapter 7: Broader impacts, Conclusion and Future Work
7.1. Broader impacts
FIRMS is an analytical technique that should expand IR research to any scientist
with access to a tandem MS. Unlike the current approaches, where IR analysis is available
to a relatively small number of facilities that can afford to purchase, staff, and maintain IR
analysis instruments, the tandem MS instruments are more readily available. Moreover,
FIRMS can be directly coupled to analytical separation techniques, such as LC and GC, to
aid in determination of IRs of compounds from complex mixtures without the need for
combustion. The disciplines that will benefit from development of FIRMS include: 1)
forensic science, 2) environmental chemistry, 3) geology, 4) geochemistry, 5)
cosmochemistry, 6) food sciences, 7) earth science, and 8) pharmaceutical science. FIRMS
will make IR analysis more widely available and less expensive for scientists to conduct
research in these fields, as well as train new graduate students for future scientific research
and development in this area.

7.2. Conclusion
FIRMS was developed as a novel laboratory based analytical technique for the
analysis of 13C and 15N isotope ratios with the potential for simultaneously analyzing
other isotopes, such as 2H, 18O, 34S, 81Br, and 37Cl, with further development. This
technique also showed the ability to accurately calculate IRs when coupled with LC.
FIRMS showed excellent precision and accuracy compared to IRMS, validating FIRMS
as an accurate isotope ratio measurement technique. FIRMS is relatively economical,
fast, able to evaluate IRs with a small amount of sample (i.e., g), does not lead to loss of
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structural information for organic compounds, is self-standardizing, and can
simultaneously evaluate IRs for a mixture of compounds. Moreover, FIRMS uses MSMS technology, which has the ability to detect nM concentrations and is more readily
available than IRMS.
7.3 Future work
FIRMS is still a work in progress that requires more data collection and improved
modeling. Future research should include analysis of isotope ratios of mixtures separated
by LC and GC. It should also involve analysis of FIRMS functions as a multi-objective
optimization problem rather than single objective optimization problem. FIRMS’s full
potential will only be realized with extension to the simultaneous analysis of 2H and
other isotopes, such as 2H, 15N, 18O, 34S, 81Br, and 37Cl. Thus, future work should
expand FIRMS analysis of other isotopes. Eventually, a comprehensive study of FIRMS
applications to other disciplines including: 1) forensic science, 2) environmental
chemistry, 3) geology, 4) geochemistry, 5) cosmochemistry, 6) food sciences, 7) earth
science, and 8) pharmaceutical science should also be conducted.

108

109
Appendix A
All MRM method tables for all compounds analyzed by FIRMS including the one
that were not validated using IRMS.

Table 1. MRM method for p-toluene sulfonyl chloride including declustering potential
(DP) and collision energy (CE) measured in volts (V).

Precursor Ion
190.2
190.2
190.2
190.2
190.2
191.1
191.1
191.1
191.1
191.1
191.1
191.1
191.1

Product Ion
65.0
77.1
91.1
144.2
160.1
65.0
65.9
77.1
78.1
143.9
145.1
160.1
161.1

DP(V)
64.75
238.4
277.9
264.36
226.51
14.73
74.16
79.53
167.29
228.52
195.97
48.44
210.34

CE(V)
68.21
87.44
36.54
27.52
38.77
55.56
60.20
61.73
70.66
24.98
31.54
20.22
12.72

Table 2. MRM method for Eugenol including declustering potential (DP) and collision
energy (CE) measured in volts (V).

Precursor Ion
164.2
164.2
164.2
164.2
164.2
165.2
165.2
165.2
165.2
165.2
165.2
165.2
165.2
165.2
165.2

Product Ion
78.0
91.0
94.0
103.1
131.1
78.0
79.0
91.1
92.1
94.1
95.0
103.1
104.1
131.1
132.1

DP(V)
90.35
150.4
159.18
163.4
175.03
156.86
154.41
159.8
154.39
152.32
157.46
158.65
174.72
152.13
153.34

CE(V)
35.22
31.89
47.68
29.68
22.19
42.65
32.48
38.25
33.81
38.85
30.27
35.35
29.29
32.38
21.12
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Table 3. MRM method for o-tert-butyl-l-tyrosine including declustering potential (DP) and
collision energy (CE) measured in volts (V).

Precursor Ion
238.3
238.3
238.3
238.3
238.3
238.3
239.2
239.2
239.2
239.2
239.2
239.2
239.2
239.2
239.2
239.2
239.2
239.2

Product Ion
57.0
91.1
119.1
123.1
136.1
165.0
57.2
58.1
91.1
92.0
119.2
120.1
123.0
124.1
136.1
137.1
165.1
166.0

DP(V)
66.78
60.17
27.90
103.43
62.84
50.47
144.41
61.38
51.08
13.14
92.64
43.14
79.30
104.57
67.84
43.15
76.93
58.06

CE(V)
51.44
61.39
37.69
35.26
22.90
16.69
52.81
75.01
74.89
44.58
42.61
38.17
30.11
37.83
22.69
21.15
19.38
18.73

Table 4. MRM method for L-tyrosine including declustering potential (DP) and collision
energy (CE) measured in volts (V).
Precursor Ion
182.1
182.1
182.1
182.1
183.1
183.1
183.1
183.1
183.1
183.1
183.1
183.1

Product Ion
91
125.8
153.7
164.9
91.0
92.1
125.9
126.9
153.8
155.2
165.1
166.0

DP(V)
35.56
157.37
115.37
54.84
66.62
37.69
14.19
87.78
178.88
177.09
81.86
98.39

CE(V)
40.22
24.64
7.98
13.71
40.45
41.74
9.49
9.25
63.46
13.34
14.03
14.26
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Table 5. MRM method for 3-phenyl propionic acid including declustering potential (DP)
and collision energy (CE) measured in volts (V).
Precursor Ion
150.0
151.2
151.2

Product Ion
91.1
91.1
92.1

DP(V)
83.56
60.23
118.09

CE(V)
31.89
26.07
32.53

Table 6. MRM method for p-toluene sulfonic acid including declustering potential (DP)
and collision energy (CE) measured in volts (V).
Precursor Ion
171.0
171.0
171.0
172.0
172.0
172.0
172.0
172.0
172.0

Product Ion
77.1
79.9
106.9
77.1
78.0
79.9
80.9
107.0
108.1

DP(V)
-57.80
-41.81
-37.64
-107.68
-110.78
-100.41
-84.30
-13.53
-81.30

CE(V)
-47.07
-25.87
-26.59
-37.19
-31.93
-42.31
-39.86
-30.07
-27.07

Table 7. MRM method for 3, 4-dibromo benzaldehyde including declustering potential
(DP) and collision energy (CE) measured in volts (V).
Precursor Ion
263.1
263.1
263.1
263.1
263.1
264.2
264.2
264.2
264.2
264.2
264.2
264.2
264.2

Product Ion
75.0
79.1
105.2
156.0
234.9
75.1
76.0
105.1
106.1
156.0
157.0
234.9
235.9

DP(V)
260.61
166.37
205.72
214.05
223.54
269.37
270.78
4.81
67.83
226.68
249.22
223.81
208.33

CE(V)
65.67
73.65
60.62
41.60
36.82
80.79
75.59
54.28
61.81
46.85
49.46
38.67
32.92
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Table 8. MRM method for 2, 3-dicyano hydroquinone including declustering potential
(DP) and collision energy (CE) measured in volts (V).
Precursor Ion
159.7
159.7
159.7
161.2
161.2
161.2
161.2
161.2
161.2

Product Ion
77.0
105.0
131.0
77.0
77.9
105.1
106.1
131.0
132.0

DP(V)
-139.91
-137.31
-147.10
-138.49
-131.04
-158.6
-145.99
-130.58
-133.07

CE(V)
-29.44
-31.43
-33.15
-28.05
-24.90
-17.12
-33.40
-37.69
-32.73

Table 9. MRM method for 4 – nitro benzaldehyde including declustering potential (DP)
and collision energy (CE) measured in volts (V).
Precursor Ion
150.0
150.0
150.0
151.1
151.1
151.1
151.1
151.1
151.1

Product Ion
76.0
92.1
121.9
76.1
77.2
92.1
93.1
121.9
122.8

DP(V)
-139.58
-33.54
-36.50
-131.08
-24.90
-50.54
-34.80
-61.36
-30.09

CE(V)
-32.08
-17.34
-6.25
-19.05
-25.80
-33.75
-29.31
-16.36
-15.94

Table 10. MRM method for 5-chloro-2methyl benzoic acid originating from China
including declustering potential (DP) and collision energy (CE) measured in volts (V).
Precursor Ion
171.1
171.1
171.1
171.1
172.1
172.1
172.1
172.1
172.1
172.1
172.1
172.1

Product Ion
91.0
125.1
141.3
153.1
91.0
92.1
125.1
125.9
141.0
141.9
153.3
154.1

DP(V)
23.68
91.38
254.36
21.33
235.06
69.39
98.35
51.98
276.6
224.73
139.26
76.43

CE(V)
26.07
34.26
52.34
26.80
48.73
34.71
19.10
26.49
86.63
64.70
27.33
16.69
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Table 11. MRM method for 5-chloro-2methyl benzoic acid originating from India
including declustering potential (DP) and collision energy (CE) measured in volts (V).
Precursor Ion
171.2
171.2
171.2
171.2
172.2
172.2
172.2
172.2
172.2
172.2
172.2
172.2

Product Ion
91.0
125.1
141.2
153.1
91.1
92.0
125.0
126.0
141.1
142.1
153.3
154.1

DP(V)
77.31
124.5
253.75
23.65
138.67
105.51
18.12
23.81
250.6
241.26
66.05
78.98

CE(V)
32.25
35.06
59.62
23.39
32.68
31.64
27.13
52.30
104.16
49,97
60.11
19.30

Table 12. MRM method for ethyl methyl phosphonic acid including declustering potential
(DP) and collision energy (CE) measured in volts (V).
Precursor Ion
123.0
123.0
123.0
123.9
123.9
123.9
123.9
123.9
123.9

Product Ion
77.0
78.9
94.9
76.7
77.8
78.9
79.9
94.8
95.8

DP(V)
-23.56
-14.48
-19.25
-18.49
-106.16
-54.56
-48.23
-62.35
-73.50

CE(V)
-17.87
-29.61
-11.93
-36.80
-32.07
-38.24
-36.41
-16.54
-15.50
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